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Due to the outbreak of COVID-19, all recruitment for research projects in NHS Ayrshire and 
Arran was suspended on 16th March 2020. By this time, a portion of the required sample for 
the major research project in this thesis had already been recruited. The University later 
confirmed that projects could be presented for examination in which some usable data had 
been collected, but the nature or amount of the data differs from what was planned in the 
proposal. This major research project met these criteria and is therefore presented in this 
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5 
 
Table of Contents 
Chapter 1: Systematic Review .................................................................... 7 
Abstract .................................................................................................................................. 8 
Introduction ............................................................................................................................ 9 
Methods ................................................................................................................................ 10 
Results .................................................................................................................................. 13 
Discussion ............................................................................................................................ 27 
Conclusions .......................................................................................................................... 28 
References ............................................................................................................................ 30 
Chapter 2: Major Research Project ........................................................... 38 
Plain English Summary ........................................................................................................ 39 
Abstract ................................................................................................................................ 41 
Introduction .......................................................................................................................... 42 
Methods ................................................................................................................................ 45 
Results .................................................................................................................................. 48 
Discussion ............................................................................................................................ 57 
References ............................................................................................................................ 60 
Chapter 3: Appendices ............................................................................. 64 
Appendix A. Author guidelines for submission to Movement Disorders Journal ............... 64 
Appendix B. Ten steps for conducting a systematic review of PROMS (Reprinted from 
with permission from the COSMIN manual  (Mokkink et al., 2018). ................................. 67 
Appendix C. Modifications made to COSMIN guidance .................................................... 69 
Appendix D Additional modifications made to COSMIN guidance ................................... 70 
Appendix E. Screenshot of search terms in EBSCOhost database. ..................................... 72 
Appendix F. Risk of bias procedure. .................................................................................... 73 
Appendix G. Descriptions of each measure included for review ......................................... 76 
Appendix H. Breakdown of instruments by language ......................................................... 80 
6 
 
Appendix I.  Risk of bias additional information by measurement property ....................... 88 
Appendix J. Author guidelines for submission to the Parkinson’s Disease Journal ............ 89 
Appendix K. Copy of R&D approval ................................................................................... 91 
Appendix L. Ethics approval letter ...................................................................................... 93 
Appendix M. Distress Thermometer and problem list. ........................................................ 96 
Appendix N. Additional Questionnaire ................................................................................ 97 
Appendix O. Additional information regarding recruitment. ............................................ 100 
Appendix P. Flowchart of recruitment ............................................................................... 101 
Appendix Q. Major Research Project Protocol .................................................................. 102 
 
List of Figures 
Figure 1.1: PRISMA flowchart displaying numbers for each stage of the review process. IPD 
= Idiopathic Parkinson’s Disease. ............................................................................................ 14 
 
List of Tables 
Chapter 1: Systematic Review 
Table 1.1: Psychometric Properties of the Instruments (Structural Validity; Internal 
Consistency; Reliability; Measurement Error). .................................................................... 18 
Table 1.2: Psychometric Properties of Instruments Continued (Construct Validity and 
Criterion Validity). ............................................................................................................... 23 
Chapter 2: Major Research Project 
Table 2.1: Demographic characteristics of the sample (N =40). .......................................... 49 
Table 2.2: Descriptive statistics for clinical measures. ........................................................ 50 
Table 2.3: Descriptive statistics for Movement Disorder Problem List pre and post 
appointment. ......................................................................................................................... 52 
Table 2.4: Types of problems endorsed from the Movement Disorder Problem List. ........ 53 
Table 2.5: Correlations between the Distress Thermometer score and number of problems 
endorsed. .............................................................................................................................. 56 
7 
 
 
Chapter 1: Systematic Review 
A Systematic Review of Health-Related Quality of Life Measurements for 
Parkinson’s Disease across Cultures 
Bronagh Reynolds,  MSc,1,2 , Emma Mawdsley, MSc1 and Breda Cullen, PhD1   
1 Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, 
University of Glasgow. 
2 NHS Ayrshire and Arran  
Correspondence to: Institute of Health and Wellbeing, College of Medical, Veterinary and 
Life Science, University of Glasgow, 1st floor, Administration Building, Gartnavel Royal 
Hospital, 1055 Great Western Road, Glasgow, G12 0XH 
Bronagh Reynolds 2356262r@student.gla.ac.uk 
Prepared in accordance with submission requirement for the Movement Disorder Journal (see 
Appendix A, page 64). 
Word count including abstract references: 6,888 
  
8 
 
Abstract 
Background: Health-related quality of life (HRQoL) is a key construct to assess in people 
with Parkinson’s disease. Many HRQoL measures have been translated for use in different 
countries. Despite the proliferation in studies translating quality of life measures, there is no 
systematic review evaluating the psychometric properties of these translated measures. 
Objective: The primary aim of this review was to evaluate the psychometric properties of 
nine HRQoL measures recommended for use in people with Parkinson’s disease after they 
have been translated into a different language. 
Method: Four databases were systematically searched. Studies which involved validation of 
one of the nine measures in a different language and/or adaptation of the measure were 
included for review. The Consensus-based Standards for Measurement Instruments guidance 
was used for data extraction and for rating risk of bias. 
Results: After databases were searched, 5,451 papers were found and after screening a total 
of 33 papers were included for review representing six out of the nine measures. Internal 
consistency and construct validity were the measurement properties most commonly reported 
by the studies reviewed. Issues regarding unidimensionality of measures were noted along 
with limited transparency of the translation process. 
Conclusion: Of the six measures reviewed, the PDQ-39 shows promise in Chinese and 
Filipino, along with the SCOPA-PS in French and potentially the SCOPA-PS in other 
languages reviewed, if evidence for unidimensionality is clarified and reliability is further 
evidenced. 
Keywords: Parkinson’s Disease; health-related quality of life; translation; validation; 
reliability 
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Introduction 
Parkinson’s disease (PD) is a neurodegenerative disease affecting both motor and non-motor 
functioning with symptoms fluctuating and progressing over time, causing significant 
changes in health-related quality of life (HRQoL). PD symptoms fluctuate and change over 
time meaning that it is important to be able to accurately assess and track HRQoL over time. 
For the purposes of this review, HRQoL is the subjective judgement of “the physical, 
emotional and social wellbeing and satisfaction related to health” (Martinez-Martin, Jeukens-
Visser, Lyons, Rodriguez-Blazquez, et al., 2011, p. 2372).  
In 2011, a Movement Disorder Society (MDS) Taskforce was commissioned to conduct a 
review of measures used to assess HRQoL in Parkinson’s disease (Martinez-Martin, Jeukens-
Visser, Lyons, Rodriguez-Blazquez, et al., 2011). A total of 17 measures were reviewed and 
graded according to predefined criteria and catalogued as either ‘recommended’, ‘suggested’ 
or ‘listed’. Nine patient reported outcome measures (PROM) were graded as being 
‘recommended’ for use.  
These measures are therefore the most likely ones to be employed in different aspects of 
research and clinical care involving people with PD worldwide. The importance of 
appropriately translating and validating HRQoL measures to the applicable culture has been 
noted in the literature along with suggestions on how this may be done effectively. There are 
several key reasons why this is important for people with PD. These include areas of health 
care research and economics as well as policy and local clinical practice.  
Firstly, research into potentially efficacious treatments is ongoing in PD. An intervention may 
be deemed beneficial if it leads to symptom reduction; however, it may be a distressing or 
unpleasant experience for the individual or result in side effects which greatly limit their 
independence. The subjective nature of HRQoL needs to be accurately captured to give a 
balanced picture of the impact of an intervention (NICE, 2017).  The emergence of promising 
treatments will likely encourage larger scale international clinical trials encompassing 
different languages and cultures, making it vital that measures validated in these countries 
have comparable psychometric properties to the original measure.  
Secondly, regarding health care economics, HRQoL instruments play a pivotal role, both in 
the UK and countries such including Germany and Spain, (Rios-Diaz et al., 2016) in 
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determining resource allocation for treatments. HRQoL, along with mortality rates, are 
combined to form quality adjusted life years (QALY) (Whitehead & Ali, 2010). The 
calculation of QALYs is central to ascertain the cost effectiveness of interventions, such as 
deep brain stimulation treatment for PD, and therefore inform health care policy and 
guidance.  
Thirdly, at a more local, individual level, adaptation of HRQoL instruments is relevant as it is 
recognised that there is an increase in multiculturalism and linguistic diversity across Europe 
(Chriost & Thomas, 2008). Therefore, healthcare professionals require access to appropriate 
instruments to assess HRQoL, in the language used by the person to communicate. This is a 
crucial part of ensuring ethical and equitable practice as one aspect of HRQoL, psychological 
distress, is known to be commonly under-reported in this population (Chen & Marsh, 2014). 
Assessing distress in this way also allows clinicians to evidence their decision-making 
processes and informs the consideration of appropriate care pathways.  
The aim of this systematic review was to examine the psychometric properties of MDS-
recommended HRQoL measures for PD after they have been translated into a language other 
than that in which they were originally developed. A secondary objective was to examine 
whether any adaptations beyond translation into native language (e.g. alteration/removal of 
items) have taken place, as this has implications for the validity and reliability of the 
measure.  
Methods 
Review Framework and Protocol 
This systematic review was conducted and reported in accordance with the COnsensus-based 
Standards for the selection of health Measurement INstruments (COSMIN) guidance 
(Mokkink, Prinsen, et al., 2018) and the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) guidelines (Shamseer et al., 2015). COSMIN are an 
international initiative who aim to improve the selection of health measurement instruments 
for research and in clinical practice (Mokkink, Prinsen, et al., 2018).  
The guidance offered in its most recent manual aids in structuring and conducting systematic 
reviews on PROMs (see Appendix B, page 67). A modified approach was used for this 
review with not all steps outlined deemed necessary for the purposes of this review (see 
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Appendix C, page 69). Eight of the ten measurement properties listed by COSMIN were 
extracted for this review (structural validity; internal consistency; reliability; cross-cultural 
validity; responsiveness; measurement error; criterion validity and hypothesis testing for 
construct validity). For additional details on modifications made to COSMIN guidance see 
Appendix D, page 70.The protocol for this systematic review was registered on PROSPERO 
(CRD42019139161) and can be accessed at: 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=139161 
Eligibility Criteria 
The nature of this review does not fit within widely used frameworks such as PICOS, but the 
criteria were developed systematically in consultation with the research supervisor and a 
specialist librarian. The following inclusion criteria were used to identify relevant articles: 
study population was people with the most commonly reported type of PD, idiopathic 
Parkinson’s Disease (IPD); study focused on one of the nine MDS-recommended HRQoL 
measures; study involved translation of the measure; study involved validation of the 
measure.  
Also, if the HRQoL measure used in a relevant study was translated and adapted in some 
form, the study was eligible to address the secondary review objective. If papers did not state 
whether PD participants had a specific diagnosis of IPD, this was assumed. The comparator 
used was the psychometric properties as set out by COSMIN. Only peer reviewed journal 
articles were included. Non-English language articles were eligible, but the title and abstract 
must be available in English, for screening purposes.  
Information Sources and Search Strategy 
Searches were performed in MEDLINE, Web of Science, CINAHL and PsycINFO databases, 
from inception up to October 19th, 2019. A combination of the following search terms was 
used: (Parkinson* disease questionnaire-39 or PDQ-39 or Parkinson* Disease Questionnaire-
8 or PDQ-8 or Parkinson* Impact Scale or PIMS or Medical Outcomes study-short form 36 
or SF-36 or scales of outcomes in Parkinson* disease psychosocial questionnaire or scopa-ps 
or euroqol or eq-5d or sickness impact profile or sip or nottingham health profile or nhp or 
parkinson* disease quality of life questionnaire or pdql) AND (cross-cultural or translat* or 
valid* or reliability or quality of life or health status) AND (Parkinson’s Disease). See 
Appendix E on page 72 for a screenshot of search terms. To ensure literature saturation, the 
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‘cited by’ function available only in the Web of Science database was used. This found every 
article that has cited the original article in which each of the nine instruments was first 
published. 
Study Selection 
A two-phase screening approach was used. In phase 1, titles and abstracts were screened 
against the inclusion criteria by the first author (BR) with a second reviewer (EM) 
independently screening 50 results. In phase 2, articles that appeared relevant were obtained 
and read in full by the first author. EM independently reviewed 10 full text papers. 
Disagreements were resolved by discussion until consensus was reached.  
Risk of Bias Assessment 
The COSMIN Risk of Bias Checklist (Mokkink, de Vet, et al., 2018) was used in this review. 
The risk of bias for each of the eight measurement properties was assessed separately for 
each study by BR with three papers reviewed independently by EM, and consensus then 
reached by discussion. The risk of bias in relation to that measurement property was then 
rated either ‘very good’, ‘adequate’, ‘doubtful’, ‘inadequate’ or ‘not applicable’ according to 
predetermined criteria set out in the checklist, and using a ‘worst counts score’ approach to 
overall rating for each property. Details of this procedure are given in Appendix F page 73. 
Data Extraction and Synthesis 
Extraction of data from included papers was conducted by the primary reviewer and 
replicated for three papers by the secondary reviewer. Discrepancies were resolved through 
discussion until consensus was reached. The eight relevant measurement properties outlined 
by COSMIN (Mokkink, Prinsen, et al., 2018) were used to structure data extraction and 
synthesis for each study separately, with a rating of (+) sufficient, (-) insufficient or (?) 
indeterminable given. This rating convention is based on the one set out by Terwee et al 
(2007) and Prinsen et al (2016). In general, a sufficient (+) rating is achieved when the figure 
is greater than or equal to .70 which is the case for internal consistency, reliability and 
criterion validity. Template tables provided by COSMIN were used for this purpose. For the 
measurement property (hypotheses testing for construct validity), the following set of Apriori 
hypotheses (suggested by COSMIN) were formulated against which to evaluate the results of 
the studies. Correlations between measures evaluating similar constructs were expected to be 
≥.50. Correlations were expected to be ≥.30 with measures evaluating related but dissimilar 
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constructs (e.g. specifically motor aspects of PD only). Correlations were expected to be <.30 
with instruments measuring unrelated constructs. Number of participants and any adaptations 
to the content of the instrument were also extracted. Due to the expected heterogeneity 
amongst studies, it was decided a priori that data would be summarised qualitatively, with no 
meta-analysis conducted. 
Results 
A total of 42 studies were deemed eligible for inclusion; see PRISMA-P flow chart in Figure 
1 below. Four studies conducted evaluations of multiple measures in multiple languages. This 
meant that the total number of data points would be 49. Given the time scale required for 
completion of the review, it would not have been possible to review each data point to the 
standard required. In addition, the review by Martinez-Martin et al (2011) posited their nine 
‘recommended’ measures, so there was a high likelihood that these measures would be more 
frequently studied and employed in relevant translation studies after, rather than before this 
date. As such, studies conducted in the past 15 years were included which meant (2004-2019 
inclusive) that no relevant measure was missed, and no language was missed. Several of the 
studies which were not included were replicated/subsumed by future work which was 
included e.g. Spanish version of the PDQ-39 was conducted in 1999 but this study was 
replicated again in 2005, and so is included in this review.  
Therefore, studies conducted in the past 15 years (2004-2019 inclusive) were therefore 
included. This resulted in 33 studies being included, representing six of the nine instruments 
of interest (PDQ-39; PDQ-8; PIMS; EQ-5D; SCOPA-PS; PDQL); see Appendix G, page 76 
for further details on each measure. The other three (NHP; SIP; SF-36) were not studied in 
any eligible paper from the past 15 years or earlier.
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Figure 1.1: PRISMA flowchart displaying numbers for each stage of the review process. IPD 
= Idiopathic Parkinson’s Disease. 
There was a high level of agreement between reviewers in both phase 1 (98%) and 2 (97.5%). 
Four of the included studies conducted multiple evaluations of an instrument/language which 
resulted in a total of 40 sets of results which were reviewed. Fifteen sets of results were 
reviewed for the PDQ-39; nine for the PDQ-8; nine for the SCOPA-PS; four for the PDQL, 
two for the PIMS and one for the EQ-5D. A total of 17 languages were evaluated across the 
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six instruments. Spanish, Chinese and Portuguese were the most common language 
translations. For Spanish and Chinese languages, dialects varied across studies e.g. 
Ecuadorian Spanish, Singaporean Chinese or mainland Chinese. A breakdown of each 
instrument by language is given in Appendix H page 78.   
Tables 1.1 and 2.1 below present the psychometric properties of all the instruments including 
risk of bias ratings for each. There was heterogeneity across studies regarding which 
measurement properties were reliably assessed and how these were subsequently reported; 
however, none of the studies evaluated cross-cultural validity or responsiveness and so they 
are not represented in the tables below. It was noted that construct validity (40 results) and 
internal consistency (39 results) were the most assessed, followed by reliability (20 results) 
and structural validity (16 results). Data extraction accuracy of reviewers BR and EM was 
high (97% agreement). Interpretation of the below results requires examination of both the 
risk of bias ratings and the related figures, or each measurement property assessed. Ideally, 
the risk of bias rating would be very good (V) or adequate (A) indicating a relatively low risk 
of bias for that property. Risk of bias ratings need to be considered alongside the 
measurement property figure as a low risk of bias may exist alongside a figure deemed 
insufficient (-) according to COSMIN. An example of this is Carod‐Artal, Martinez‐Martin, 
& Vargas (2007) who translated the PDQ-39 into Portuguese. They found that the reliability 
of the measure had a low risk of bias for reliability as well as an insufficient rating for the 
reliability figure. This indicates that the reliability of the PDQ-39 in this study was below the 
recommended level, and that this result is likely to be trustworthy as the methods showed low 
risk of bias. Overall, there is a pattern of a relatively high risk of bias throughout the 
measures presented in tables 1.1. and 1.2 below, with typical ratings of doubtful (D) and 
inadequate (I) being given for figures. This is commented on below in the risk of bias section. 
To interpret the results of this review, then, particular attention should be paid to the ratings 
of sufficient (+), insufficient (-) or indeterminable (?), as well as risk of bias ratings, as those 
figures which meet sufficient criteria, typically have a relatively high risk of bias in this 
review. In addition, some languages are represented more than others, and so this allows for 
sufficient ratings to be replicated across studies in the same language. This should also be 
taken into account when interpreting the results. For these reasons, the PDQ-39 in Chinese 
which was reviewed four times, shows promise, although sufficient results display a 
generally high risk of bias which is typical across all measures reviewed. Although in the 
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Chinese language, different dialects were used and thus readers interested in specific region 
of China may wish to pay special attention to the individual findings. 
The PDQ-39 in Filipino shows promise as it is one of the only studies to find the internal 
consistency of both the subscales, and overall summary index figures to be sufficient. This is 
of interest and in contrast to, most of the other results for internal consistency and the PDQ-
39, as the subscales were either insufficient, or not reported in favour of the summary index 
score.  
The SCOPA-PS is not the most widely researched measure but when translated into French, 
many of the relevant measurement properties were examined and found to be sufficient. This 
needs to be interpreted in the context of a high risk of bias for the measurement properties. 
Given the heterogeneity  of the properties reported and the generally high risk of bias for 
these, conclusions about which measures are the most valid and reliable are not 
straightforward, and  so additional interpretations than the one made above are also possible. 
The presentation of the results in table format allows the reader to examine the results 
independently and facilitates closer inspection of a measure or language of interest as desired.  
Structural validity 
Structural validity of the PDQ-39, PDQ-8 and SCOPA-PS was assessed. Only two papers 
calculated a statistic deemed appropriate by COSMIN (20 & 32 in Table 1), for the PDQ-8 
and SCOPA-PS respectively, although neither met the ‘sufficient’ criteria. There was 
heterogeneity across studies regarding whether a one or multiple factor model was 
appropriate, e.g. for the SCOPA-PS a one factor model was found by Soulas et al. (2016) but 
a two-factor model posited by (Martinez-Martin et al., 2009) (32 & 40 in Table 1).  
Internal consistency, reliability and measurement error 
Variations in reporting of subscale and summary index results were noted for both internal 
consistency and reliability measurement properties, with only six studies reporting on both 
the subscale and summary index. Of these, only two studies found ‘sufficient’ internal 
consistency for both subscales and the summary index, for the Chinese and Filipino versions 
of the PDQ-39 (4 and 14 in Table 1). Only two results were available for measurement error 
(32 & 40 in Table 1), for the SCOPA-PS French and Spanish versions, although the methods 
used were deemed inadequate according to COSMIN as the standard error of the mean was 
calculated from one time point only. 
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Criterion validity and construct validity 
Three studies assessed criterion validity with all meeting ‘adequate’ criteria. Results for 
convergent validity were mixed. Overall, there was a pattern of correlations above .50 for 
measures which were hypothesised to be related although this varied between subscales and 
summary index results.  
For discriminant validity, the most used comparator was the Hoehn and Yahr scale, based on 
the hypothesis that groups at different disease stages would differ in their HRQoL ratings. 
However, some studies reported p values from between-group hypothesis tests, without 
interpreting the magnitude or direction of differences between groups. This resulted in an 
‘inadequate’ rating according to COSMIN criteria. 
Risk of bias 
For many studies, several factors were determined to result in a high risk of bias: small 
sample size for structural validity analysis; inappropriate time interval for test re-test 
reliability, and evidence of multidimensionality of measures. For more details see Appendix I 
page 86 . Risk of bias rating concordance for reviewers BR and EM was high with 94.4% 
agreement. 
Adaptations to content 
Although in many studies cultural adaptions were stated as having been made, the details of 
these changes were not reported. In their translation of the PDQ-39 into Estonian, Krikmann, 
Taba, Lai, and Asser (2008) changed the distance conversion system so that metric units were 
used in the translated version. This was the only change made that was explicitly detailed by 
any study included in this review. 
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Table 1.1: Psychometric Properties of the Instruments (Structural Validity; Internal Consistency; Reliability; Measurement Error). 
 
Author (Year) PROM Country (language in which 
the questionnaire was 
evaluated) 
Structural validity Internal consistency 
 
Reliability 
 
Measurement Error 
No. RoB Result 
(Rating) 
No. RoB Subscale 
rating 
SI 
rating 
No. RoB Subscale 
rating 
SI 
rating 
No. RoB Rating 
1. (N. Luo, Low, Lau, Au, 
& Tan, 2009) 
EQ-5D Singapore(Chinese)  N (?)  N (?) (?)  N (?) (?)  N (?) 
2. (Martinez-Martin, 
Serrano-Duenas, & 
Vaca-Baquero, 2005) 
PDQ-39 Ecuador(Ecuadorian 
Spanish) 
  N (?) 137 D .48-.92(-)  (?)   N (?) (?)  N (?) 
3. (Nojomi, Mostafavian, 
Shahidi, & Jenkinson, 
2010) 
PDQ-39 Iran(Persian)   N (?) 200 D .60-.91(-) .93(+) 200 I .47-.90(-) .80(+)  N (?) 
4. (W. Luo et al., 2010) PDQ-39 China(Chinese)   N (?) 71 D .86-.88(+) .84(+) 71 I .56-.82(-)  .82(+)  N (?) 
5. (Žiropađa, Stefanova, 
Potrebić, & Kostić, 
2009) 
PDQ-39 Serbia(Serbian) 102 I PCA(?) 102 D .59-.91(-)  (?)   N (?) (?)  N (?) 
6. (Zhang & Chan, 2012) PDQ-39 China(Chinese)   N (?) 126 D .54-.91(-) (?)    N (?) (?)  N (?) 
7. (Park, Sohng, & Kim, 
2014) 
PDQ-39 Korea(Korean) 93 I EFA(?) 93 D .70-.97(+)  (?)   N (?) (?)  N (?) 
8. (Krikmann et al., 2008) PDQ-39 Estonia(Estonian)   N (?) 137 D .81-.86(+)  (?) 78 D  (?) (?)  N (?) 
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9. (N. Luo, Tan, Li, Soh, & 
Thumboo, 2005) 
PDQ-39 Singapore(Chinese) 63 I PCA(?) 63 D .64-.90(-) .74(+) 36 I .66-.86(-) (?)  N (?) 
10. (Ma, Hwang, & Chen-
Sea, 2005) 
PDQ-39 China(Chinese)   N (?) 73 D .58-.96(-)  (?) 22 I .71-.95(+) (?)  N (?) 
11. (Carod‐Artal, Martinez‐
Martin, & Vargas, 2007) 
PDQ-39 Brazil(Portuguese)   N (?) 144 D .61-.85(-) (?) 144 V .52-.80(-) (?)  N (?) 
12. (Marinus, Visser, 
Jenkinson, & 
Stiggelbout, 2007) 
PDQ-39 Holland(Dutch)   I (?) 177 D .59-.91(-) (?)   N (?) (?)  N (?) 
13. (Kwon et al., 2013) PDQ-39 Korea(Korean)   N (?) 102 D .58-.80(-)  (?) 101 I  (?) (?)  N (?) 
14. (Suratos, Saranza, 
Sumalapao, & Jamora, 
2018) 
PDQ-39 Philippines(Filipino)   N (?) 30 D .86-.88(+) .85(+)   N (?) (?)  N (?) 
15. (Galeoto et al., 2018) PDQ-39 Italy(Italian)   N (?) 104 D .69-.92(-)  (?) 35 I .85-.96(+) (?)  N (?) 
16. (Jesus-Ribeiro, Vieira, 
Ferreira, Januário, & 
Freire, 2017) 
PDQ-39 Portugal(Portuguese)  N (?) 100 D .66-.98(-) (?) 13 I .49-.96(-) (?)  N (?) 
17. (Katsarou et al., 2004) PDQ-8 Greece(Greek)   N (?) 228 D (?) .72(+) 91 I (?) .72(+)  N (?) 
18.  
(Tan, Lau, Au, & Luo, 
2007) 
PDQ-8 China(Chinese) 79 I PCA(?) 79 D (?) .87(+) 79 N (?) (?)  N (?) 
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19. (Kahraman et al., 2018) PDQ-8 Turkey(Turkish)   N  (?) 83  D (?) .78(+) 24 I (?) .97(+)  N (?) 
20. (Huang, Hsu, Wang, & 
Chen, 2011) 
PDQ-8 Taiwan(Chinese) 100 V CFI .95(+) 
RMSEA 
.08(-) 
100 D (?) .81(+)  N (?) (?)  N (?) 
21. (Franchignoni, 
Giordano, & Ferriero, 
2008) 
PDQ-8 (data 
pooled with 
PDQ 8/39) 
Italy(Italian) 100 D   (?)   D   (?)  .72(+)   N  (?) (?)  N (?) 
22. (Jenkinson & 
Fitzpatrick, 2006) 
PDQ-8/39 Japan(Japanese) 96 A PCA(?) 
 
96 D   (?)  .87(+)   N (?) (?)  N (?) 
23. (Jenkinson & 
Fitzpatrick, 2006) 
PDQ-8/39 Italy(Italian) 195 A PCA(?) 
 
195 D   (?)  .79(+)   N   (?) (?)  N (?) 
24. (Jenkinson & 
Fitzpatrick, 2006) 
PDQ-8/39 Spain(Spanish) 194 A PCA(?) 
 
194 D   (?)  .73(+)   N   (?) (?)  N (?) 
25. (K. Chen et al., 2017) PDQ-8/39 China(Chinese)   A PCA(?)   D   (?)  .80(+) 283 
Baseline 
D  (?) .96(+)  N (?) 
    
              101 Year 
one 
 D  (?) .96(+)  
    
              81 Year 
two 
 D  (?) .98(+)  
26. (Dereli et al., 2015) PDQL Turkey(Turkish) 89 N (?)    D (?)  .97(+) 46/51 I  (?) .82(+)  N (?) 
27. (Campos et al., 2011) PDQL Brazil(Portuguese)   N   52 D .65-.83(-)  .93(+) 21 I  (?) (?)  N (?) 
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28. (Serrano-Dueñas, 
Martı́nez-Martı́n, & 
Vaca-Baquero, 2004) 
PDQL Spain(Ecuadorian Spanish)   N   137 D .69-.85(-)     N  (?) (?)  N (?) 
29. (Jesus-Ribeiro et al., 
2017) 
PDQL Portugal(Portuguese)  N (?) 100 D .78-.98(+)  (?)  13 I .65-.96(-) (?)  N (?) 
30. (Serrano-Dueñas & 
Serrano, 2007) 
PIMS Ecuador(Ecuadorian 
Spanish) 
  N (?) 131 D .68-.87(-) .88(+)  131 A .91-.97(+) .98(+)  N (?) 
31. (Todorova & 
Stambolieva, 2007) 
PIMS Bulgaria(Bulgarian)   N (?)  40 D  (?)  .82(+)  40 I  (?) .71(+)  N (?) 
32. (Soulas et al., 2016) SCOPA-PS France(French) 154 D CFI.98(+) 
RMSEA 
.09(-)  
73 D  (?) .86(+) 73 I (?) .88(+)  I SEM calculated using 
single time point(?) 
33. (Fereshtehnejad et al., 
2014) 
SCOPA-PS Iran(Persian)   N (?) 110 D  (?)  .87(+) 110 N (?) (?)  N (?) 
34. (Carod‐Artal et al., 
2007) 
SCOPA-PS Brazil(Portuguese)   N (?) 144 D  (?) .84(+) 144 V (?) .71(+)  N (?) 
35. (Virués-Ortega et al., 
2009) 
SCOPA-PS Argentina(Local Spanish)   D (?) 61 D   (?) .92(+)   N (?) (?)  N (?) 
36. (Virués-Ortega et al., 
2009) 
SCOPA-PS Brazil(Portuguese)   D (?) 127 D   (?) .86(+)   N (?) (?)  N (?) 
37. (Virués-Ortega et al., 
2009) 
SCOPA-PS Ecuador(Local Spanish)   D (?) 75 D   (?) .87(+)   N (?) (?)  N (?) 
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38. (Virués-Ortega et al., 
2009) 
SCOPA-PS Paraguay(Guarani)   D (?) 68 D   (?) .86(+)   N (?) (?)  N (?) 
39. (Knudsen, Martinez-
Martin, & Deuschl, 
2007) 
SCOPA-PS Germany(German)   N (?) 105 D  (?) .90(+) 54  A (?) .77(+)  N (?) 
40. (Martinez-Martin et al., 
2009) 
SCOPA-PS Spain(Spanish) 387 A EFA(?) 387 D   (?) .85(+)   N (?) (?) 387 I SEM 
calculated(single time 
point)(?) 
 
CFI = Comparative fit index; EFA = Exploratory factor analysis; PCA = Principal components analysis; RMSEA = Root mean square error of approximation; 
SEM = Standard Error of the Mean; RoB = Risk of bias rating; V = Very good; A = Adequate; D = Doubtful; I = Inadequate; N = Not applicable; SI = 
summary index; (+) = Sufficient; (-)= insufficient; (?) = Indeterminable. 
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Table 1.2: Psychometric Properties of Instruments Continued (Construct Validity and Criterion Validity). 
  Author (Year) PROM Hypothesis testing for construct validity  
      
Criterion 
validity 
No. RoB 
Convergent 
validity 
RoB 
Discriminant 
validity 
Results (Rating) 
   
No. RoB Result 
(Rating) 
1. (N. Luo et al., 
2009) 
EQ-5D 71 V A EQ-5D subscales 
and H&Y  
-.05-.43(-) 
 
SI -.28(-) 
 
EQ-VAS -.37(+) 
UPDRS Motor 
-.07 to .22 (-) 
 
SI.04(-) 
 
EQ-VAS.19(-) 
Schwab and England activities of daily living -.10 
to -.60(-) 
 
SI .36(+) 
 
EQ-VAS .27(-) 
Chinese MMSE 
 
.03 to -.20(-) 
 
SI -.01(-) 
 
 
EQ-VAS .11(-) 
 N (?) 
2. (Martinez-Martin 
et al., 2005) 
PDQ-39 137 V A PDQL EV SI .91 
(+) 
H&Y stage& 
PDQ-39 SI .60 
(+) 
H&Y stage 
PDQ-39 
subscales - .22 
-.74(-) 
HADS – A SI .53(+) 
HADS-A and subscales .19-.52(-)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
HADS-D SI  .67(+) 
HADS – D& Subscales  .10-.57(-) 
UPDRS I .50(+) 
UPDRS II .71(+)
UPDRS III.46(+) 
 
N (?) 
3. (Nojomi et al., 
2010) 
PDQ-39 200 V A SF-36  
-.55 to -.61(+)  
    
N (?) 
4. (W. Luo et al., 
2010) 
PDQ-39 71 V A SF-36  -.46 to -
.69(-) 
    
N (?) 
5. (Žiropađa et al., 
2009) 
PDQ-39 102 V A SF-36 .80-.81(+) 
    
N (?) 
6. (Zhang & Chan, 
2012) 
PDQ-39 126 V A SF-36 .12-.76(-) 
    
N (?) 
7. (Park et al., 2014) PDQ-39 93 I A H&Y .04-.88(-) 
stigma 
   
93 I .10-65 
(-) 
8. (Krikmann et al., 
2008) 
PDQ-39 81 N A 
     
N (?) 
9. (N. Luo et al., 
2005) 
PDQ-39 63 V N EQ-5D .38-.76(-) 
    
N (?) 
10. (Ma et al., 2005) PDQ-39 73 V A UPDRS .42-.86(+) SF-36 -.29 to -
.93(-) 
   
N (?) 
11. (Carod‐Artal et 
al., 2007) 
PDQ-39 144 V A SF-36 Physical 
component 
summary -.26 to -
.59(-) 
SF-36 Mental 
component 
summary  -.18 
to -.51(-) 
   
N (?) 
12. (Marinus et al., 
2007) 
PDQ-39 177 V D SCOPA-PS  .82 (+) HADS-A 
.69(+) 
HADS-D 
.65(+) 
EQ-5D .63(+) 
EQ-VAS -.54(+) 
  
N (?) 
13. (Kwon et al., 
2013) 
PDQ-39 102 V N Korean 
Montgomery 
Asberg Depression 
Scale .47 to .70(-) 
SI .66(+) 
ESS-.24to.43 (-
) 
SI .40(-) 
H&Y stage .14-.35(-) 
PDQ-39 SI .36(+) 
NMSS .19-.66 
(-) 
 
N (?) 
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14. (Suratos et al., 
2018) 
PDQ-39 100 V A HADS A .32 to 
.58(-) 
SI. 61(+) 
HADS D .32-.48 (-) 
SI .52(+) 
H&Y stage & 
PDQ-39 
subscales  
.20 -.64(-) 
PDQ-39 SI 
.46(+) 
UPDRS-I .19-.42(-) 
SI .40(+) 
UPDRS II .08 to .56(-) 
UPDRS III -.14-.50(-) 
SI .51(+) 
PDQ-39 subscales 
& NMSS.12 to 
.56 (-) 
NMSS & PDQ-39 
SI . 56(+) 
 
N (?) 
15. (Galeoto et al., 
2018) 
PDQ-39 104 V N SF-36 -.50(+) 
    
N (?) 
16. (Jesus-Ribeiro et 
al., 2017) 
PDQ-39 100 V A SF-36 .03 to -.77(-)     N (?) 
17. (Katsarou et al., 
2004) 
PDQ-8 81 V V SF-36 Correlations 
for physical 
disability  
-.46(-); pain -.42(-); 
energy/vitality -
.45(-) 
BDI .58(+) 
   
V (?) 
18.  
(Tan et al., 2007) 
PDQ-8 79 V A H&Y .29(-) 
    
N (?) 
19. (Kahraman et al., 
2018) 
PDQ-8 83 V D SF-36 Physical  
-.52(+) 
SF-36 Mental 
 -.64(+) 
H&Y stage .56(+) 
  
N (?) 
20. (Huang et al., 
2011) 
PDQ-8 100 V V H&Y .09 to .59(-) 
 
SI .53(+) 
Pittsburgh 
Sleep Quality 
Index .09-.39(-) 
Schwab and England activities of daily living scale 
-.13 to -.66(-) 
 
SI -.65(+) 
Taiwanese 
Depression 
Questionnaire .32 
to 74(+) 
 
SI .71(+) 
 N (?) 
21. (Franchignoni et 
al., 2008) 
PDQ-8 
(data 
pooled with 
PDQ 8/39)3 
100 V N IPA-I .47(+) HY .38(+) UPDRS-AUL .44(+) 
  
N  
22. (Jenkinson & 
Fitzpatrick, 2006) 
PDQ-8/39 96 V N H&Y stage .47(+) 
    
V 0.92 (+) 
23. (Jenkinson & 
Fitzpatrick, 2006) 
PDQ-8/39 195 V N H&Y stage .47(+) 
   
195 V 0.96 (+) 
24. (Jenkinson & 
Fitzpatrick, 2006) 
PDQ-8/39 194 V N H&Y Stage .61(+) 
   
194 V 0.93 (+) 
25. (K. Chen et al., 
2017) 
PDQ-8/39 283 
Baseline 
V D H&Y stage.48(+) UPDRS-
III.47(+) 
BDI .64(+) ) 283 V .93 (+) 
   
101 
Year one 
  
H&Y stage .29(-) UPDRS-III 
.34(+) 
BDI .69(+) 
  
I (?) 
   
81 Year 
two 
  
H&Y stage .32 (+) UPDRS-III .43 
(+) 
BDI .69(+) 
  
N (?) 
26. (Dereli et al., 
2015) 
PDQL 89 V D H&Y SI -.55 to -
.73(+) 
 
H&Y 
-.64(+) 
UPDRS 1  
 -.60(+) 
UPDRS II   
-. 64(+) 
UPDRS III  
 -.64(+) 
UPDRS total -
.73(+) 
   
N (?) 
27. (Campos et al., 
2011) 
PDQL 52 V D Emotional domain 
of the PDQL-BR & 
Emotional 
domain of the 
   
N (?) 
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UPDRS I 59(+) 
UPDRS III .78(+) 
PDQL-BR & 
BDI .57(+) 
28. (Serrano-Dueñas 
et al., 2004) 
PDQL 137 V D HADS-A -.34 to -
.70(-) SI-.55(+) 
 
HADS-D -.45 to -
.74(-), SI -.67(+) 
UPDRS 
.32to.70(+) 
PDQ-39 -0.91(-) Schwab and 
England scale .30 
to .67 
SI  .65 
 
N (?) 
29. (Jesus-Ribeiro et 
al., 2017) 
PDQL 100 V A SF-36 .32 -.70(-)      (?) 
30. (Serrano-Dueñas 
& Serrano, 2007) 
PIMS 131 V V PDQ-39 .80(+) PDQL  
-.87(+) 
HADS Anxiety .64(+) 
HADS Depression .76(+) 
SCOPA/SPES  
A.72(+) 
B.78(+) 
C.58(+) 
Total .77(+) 
 
N (?) 
31. (Todorova & 
Stambolieva, 
2007) 
PIMS 40 V V PDQ-39 .40(-) PDQL .27(-) UPDRS II .31(+) 
UPDRS III .44(+) 
DV assessed using 
ANOVA(?) 
 
N (?) 
32. (Soulas et al., 
2016) 
SCOPA-PS 154 V V PDQ-39 .35-.73(-) 
PDQ SI  .83(+) 
BDI II .69(+) UPDRS III .49(+) STAI-Y  .56(+) 
 
N (?) 
33. (Fereshtehnejad 
et al., 2014) 
SCOPA-PS 110 V N PDQ-39 .43-.72(-) 
PDQ-39 SI .82 (+) 
HADS A .64(+) 
HADS D .72(+) 
H&Y.34(+) 
  
N (?) 
34. (Carod‐Artal et 
al., 2007) 
SCOPA-PS 144 V D SF-36 physical 
component 
summary-.42(-) 
SF-36 Mental 
component 
summary -.41(-
) 
   
N (?) 
35. (Virués-Ortega et 
al., 2009) 
SCOPA-PS 61 V D PDQ-39 .46 to .73 
(-) 
PDQ-39 SI . 85 (+) 
SCOPA-Motor 
.43(-) 
CISI-G.52(+) HADS-A  .63(+) 
HADS-D  .62(+) 
 
N (?) 
36. (Virués-Ortega et 
al., 2009) 
SCOPA-PS 127 V D PDQ-39 
.39 to 65(-) 
SI .80(+) 
SCOPA-Motor 
.51(+) 
CISI-G  0.54(+) HADS-A  .62(+) 
HADS-D  .69 
 
N (?) 
37. (Virués-Ortega et 
al., 2009) 
SCOPA-PS 75 V D PDQ-39 
.53 to .74(-) 
SI .78(+) 
SCOPA-Motor 
.59(+) 
CISI-G  0.62(+) HADS-A  .58(+) 
HADS-D  .63(+) 
 
N (?) 
38. (Virués-Ortega et 
al., 2009) 
SCOPA-PS 68 V D PDQ-39 
.17 to .76(-) 
SI .83(+) 
SCOPA-Motor 
.42(-) 
CISI-G  0.52(+) HADS-A  .57(+) 
HADS-D  .58(+) 
 
N (?) 
39. (Knudsen et al., 
2007) 
SCOPA-PS 54 V N PDQ-39 .86(+) EQ-5D -.73(+) 
EQ-VAS  .61 
(+) 
HADS A  .76(+) 
HADS D  .76(+) 
CISI-PD  .57(+) 
 
N (?) 
40. (Martinez-Martin 
et al., 2009) 
SCOPA-PS 387 V V CISI-G .18(-) EQ-5D  
-.61(+) 
HADS A .58(+) 
HADS D .67(+) 
SCOPA-AUT  
.56(+) 
SCOPA- Motor 
.52(+) 
 
N (?) 
 
ANOVA = Analysis of Variance; BDI = Beck’s Depression Inventory; CISI-G = Clinical Impression of Severity Index-Geriatric; DV = Discriminant validity 
H&Y = Hoehn and Yahr staging scale; HADS = Hospital Anxiety and Depression Scale; IPA-I = Impact on Participation and Autonomy (perceived limitations 
in participation and autonomy subscale; SCOPA-AUT = SCales for Outcomes in Parkinson’s disease - Autonomic Dysfunction; SF-36 = The 36-Item Short 
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Form Health Survey; UPDRS = Unified Parkinson’s Disease Rating Scale. RoB = Risk of bias rating; V = Very good; A = Adequate; D = Doubtful; I = 
Inadequate; N = Not applicable; (+) = Sufficient; (-)= insufficient; (?) = Indeterminable. 
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Discussion 
This review presented the psychometric properties of 33 studies, across 17 languages, which 
had translated and validated one or more of six MDS-recommended HRQoL instruments in 
PD. The findings indicate the wide variety in reporting of measurement properties which 
impacts how well the utility of an instrument can be compared and contrasted across cultures. 
This is congruent with the variable reporting of measurement properties that was highlighted 
in a previous systematic review on cross-cultural translations and adaptations of the 
Multidimensional Perceived Social Support Scale (Dambi et al., 2018).  
There was also variability in instruments used as comparators to examine convergent validity, 
resulting in mixed results for this measurement property across studies. As reported in Table 
1.1, the dimensionality of instruments was not routinely assessed despite evidence that all 
instruments in this review may be multidimensional; see supplementary material in Martinez-
Martin, Jeukens-Visser, Lyons, Roiguez-Blazquez, et al. (2011). This issue directly affects 
internal consistency and reliability as if an instrument is not unidimensional, a summary 
index result is not useful and subscale scores should be calculated instead. Given the 
variations in reporting subscale and/or summary index results in this review, adequate 
internal consistency or reliability cannot be reliably assumed for many of the instruments. 
This finding may prompt re-evaluation of the dimensionality of these measures, taking into 
account the concept of HRQoL itself is multidimensional (Lin, Lin, & Fan, 2013) and 
therefore a multidimensional instrument may be more appropriate.  
Regarding the secondary question posited, adaptations to instruments were generally not well 
defined. Transparency in reporting the translation process is essential, as it has been 
highlighted that issues such as different cultural interpretations of the word ‘family’ (as 
perhaps including only first degree or wider for example) may inadvertently lower the 
validity of the instrument (Sperber, 2004). Despite the translation process being outlined 
generally by all studies (i.e. forwards and backwards translation and review by experts), the 
more detailed process of how translation discrepancies were resolved and what these 
discrepancies were, was not described.  
Studies utilised differing translation methods e.g. MAPI Research Trust protocol; consulting 
relevant literature or simply citing methods used more broadly. This finding is similar to that 
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which has been reported in the literature e.g. Danielsen et al. (2015) who found that the 
process of translating instruments measuring HRQoL is not standardised across studies.  
Strengths and Limitations 
A strength of this review is the wide range of different languages which were included and 
therefore it allowed for multiple languages to be included and relevant measurement 
properties extracted. Another strength of the present review is the use of the detailed 
COSMIN framework to extract relevant measurement properties, conduct risk of bias ratings 
and synthesise findings. This framework allows for a standardisation of information 
presented regarding PROMs.   
A limitation of the current review is that the date range included was limited to the past 15 
years. Including all relevant studies would have resulted in comparisons in risk of bias across 
early translation i.e. from the 1990s, to present day to be considered. It would also have 
enhanced the data set so that patterns in the results of certain measures may have been 
elucidated. Despite this, covering earlier years would not have captured any of the missing 
three PROMS, and coverage went back several years prior to when the MDS taskforce 
recommendations were originally published in 2011. A second limitation is that although the 
topic is adaptations into other languages, the search was performed using English-language 
phrases and therefore results indexed in non-English language databases may have been 
missed. Nevertheless, articles were found from a very wide range of journals from around the 
world which are representative of numerous countries and languages.  
Overall, standardisation when assessing and reporting psychometric properties would 
enhance comparison across instruments for individual clinicians/researchers and future 
reviews with the COMSIN guidance being a potentially useful framework for this.  
Conclusions 
This review presents psychometric properties of six HRQoL instruments and shows that they 
are promising in assessing HRQoL across cultures. Standardised reporting of psychometric 
properties, statistical methodology and transparent translation processes are needed to better 
interpret validity and reliability of these instruments. The evidence in this review suggests 
that the PDQ-39 shows promise in Chinese and Filipino, along with the SCOPA-PS in French 
and potentially in other languages reviewed, if procedures are put in place to reduce risk of 
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bias i.e. by following COSMIN guidance, evidence for unidimensionality is clarified and 
reliability is further evidenced. 
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Plain English Summary 
 
Is the Distress Thermometer a valid measure to screen for distress in 
people with Parkinson’s disease? 
Background 
The Distress Thermometer (DT) is a very brief screening tool, originally created 
for use with people with cancer (Roth et al., 1998). Firstly, you are required to 
rate your distress from 0-10 with 10 indicating higher distress, and then you are 
asked to tick relevant problems from a problem list. As it is brief, it has become 
a popular screening tool in healthcare settings and has been found to be valid in 
other groups of people such as those with irritable bowel syndrome and 
respiratory conditions. Parkinson’s disease (PD) is a progressive condition for 
which there are treatments but no cure. As the disease progresses, people’s 
ability to do day to day tasks such as driving, shopping and managing finances 
can reduce. This understandably has a huge effect on their quality of life and 
can cause considerable distress for people. Symptoms and their progression 
vary from person to person, and so it is important to be able to identify those 
who are distressed and may benefit from further healthcare, or other, support. 
Aims and Questions 
As the DT has not been formally evaluated with people with PD previously, we 
aimed to find out if it is a useful tool to screen for distress in people with PD. 
To do this, we compared the DT to an existing measure which has been shown 
to be valid for use with people with PD, the Hospital Anxiety and Depression 
Scale (HADS). Our question was: 
• Is the Distress Thermometer a valid screening tool in people with PD? 
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Method  
People with a diagnosis of PD were recruited by PD Nurses from a movement 
disorder clinic in Ayrshire and Arran. People were excluded if they had other 
neurodegenerative conditions (apart from dementia), and all had to be aged 18 
or older and speak English. Unfortunately, due to the outbreak of COVID-19 
and subsequent lockdown restrictions, only 40 people (out of our target of 102) 
were recruited for this study. The 40 people who took part were asked to fill out 
the DT and HADS after a routine appointment with their PD Nurse. Responses 
for both measures were then analysed using statistical software to see how 
correlated (associated) the two were. The more closely correlated they are, the 
more likely it is that the DT is valid to use with people with PD.  
Results and conclusions 
Analysis revealed a large correlation between the DT and HADS, especially for 
the HADS Anxiety score. The results seem to support the use of the DT in 
people with PD, but further research with more participants is needed to say this 
for sure. Results of the study will be presented to the clinical team. 
References 
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Holland, J. C. (1998). Rapid screening for psychologic distress in men 
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Abstract 
Background: The Distress Thermometer (DT) was developed as a tool to detect 
distress in cancer patients and has since been validated across various medical conditions and 
age groups. Idiopathic Parkinson’s disease (IPD) is a progressive neurological condition that 
causes a variety of disabling motor symptoms (such as tremor, rigidity and slowness of 
movement) and non-motor symptoms including cognitive and mood disorders, and sleep 
disturbances. To date, no studies have assessed the performance of the DT for detecting 
distress in this population. 
Objective: The primary aim of this study was to determine if the DT is a valid measure to 
detect distress in patients with IPD. 
Methods: This was a prospective observational study. Participants with IPD were recruited 
from the Movement Disorder Clinic in NHS Ayrshire & Arran. The DT was administered 
along with the Hospital Anxiety and Depression Scale (HADS). To assess test-retest 
reliability, the DT was administered before and after the clinic appointment. 
Results: Forty participants took part. Large correlations were found between the DT and 
HADS anxiety (rho = 0.68, 98% confidence interval (CI) 0.38 to 0.85) and depression (rho = 
0.58, 98% CI 0.24 to 0.79). Test retest reliability was excellent (rho = 0.98, 95% CI 0.96 to 
0.99). The most frequently endorsed problems were related to difficulties sleeping and 
walking. 
Conclusions: Despite limitations of the current study, primarily the modest sample size, the 
DT may be a promising measure to assess distress in people with IPD. Further research with 
a larger IPD sample is needed. 
Keywords: Parkinson Disease; Psychological distress; validation study; surveys and 
questionnaires. 
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Introduction 
“Distress is a multi-faceted concept pertaining to a negative or unpleasant experience which 
may be psychological (i.e. cognitive, behavioural, emotional), social and/or spiritual in 
nature…” (National Comprehensive Cancer Network, 2002, p.6). Distress has been widely 
documented in the literature as negatively impacting on quality of life and can act as a barrier 
to seeking appropriate treatment (Ransom, Jacobsen, & Booth‐Jones, 2006). Distress, in 
conjunction with other factors, can lower adherence to treatment which can lead to further 
distress and treatment complications, as well as increased health care costs (Straka, Minar, 
Gazova, Valkovic, & Kyselovic, 2018). Therefore, it is essential that healthcare professionals 
are aware of the impact of distress and can screen for this in medical settings.  
There are many useful measures which assess distress such as the Hospital Anxiety and 
Depression Scale (HADS) (Zigmond & Snaith, 1983), the Brief Symptom Inventory 
(Derogatis & Melisaratos, 1983) and the Nottingham Health Profile Index of Distress (Wann-
Hansson, Klevsgard, & Hagell, 2008). One widely used, brief measure to screen for distress 
is the Distress Thermometer (DT), originally developed for use with cancer patients (Roth et 
al., 1998). It is a visual analogue scale ranging from 0-10 with individuals required to circle 
the number which best represents their levels of distress in the past week, with higher scores 
indicating higher levels of distress. They are then asked to indicate the source of this distress 
under domains including practical, family and/or emotional problems, by completing the 
accompanying problem list (PL). The application of the DT has been expanded from adult 
cancer patients to other clinical populations, such as childhood cancer survivors (Geest, Dorp, 
Pluijm, & Heuvel‐Eibrink, 2018), adolescents with schizophrenia (Bai et al., 2020), and 
people with irritable bowel syndrome (Canaletti et al., 2020). 
Another clinical population for which distress screening is important is Parkinson’s disease. 
Idiopathic Parkinson’s disease (IPD) is a progressive neurological condition that causes a 
variety of disabling motor and non-motor symptoms. Psychological distress, including 
anxiety and depression, has been widely shown to be under-reported in people with PD and to 
have a negative impact on quality of life (Chen & Marsh, 2014). As the disease progresses 
medication effectiveness decreases and the risk of experiencing an array of symptoms such as 
cognitive impairment, psychosis, pain and autonomic dysfunction increases (Brown & 
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Fernie, 2014). Over time these impairments can lead to reductions in independence such as 
the ability to carry out instrumental activities of daily living (Foster, 2014).  
Awareness of these issues has motivated clinical services to screen for distress in people with 
IPD. This is consistent with National Institute for Health and Care Excellence (NICE) 
guidelines for chronic health conditions, which state that screening tools should be used when 
depression is suspected, in order to inform stepped care interventions, with the DT mentioned 
as being a useful screening tool (National Institute for Health and Care Excellence, 2009). 
The DT is recommended for use in other chronic conditions such as epilepsy (Scottish 
Intercollegiate Guidelines Network, 2018) and neurodegenerative diseases such as dementia 
(Brechin, Codner, James & Murphy, 2020). It can be of particular use when an individual has 
motor or literacy difficulties.  
Based on NICE guidance and its established usage in chronic conditions and 
neurodegenerative conditions, the Movement Disorders Clinic (MDC) in NHS Ayrshire & 
Arran introduced the DT with an adapted PL, the movement disorder -problem list (MD-PL) 
in 2017. Prior to the introduction of the DT, distress was not routinely enquired about at the 
MDC, with the onus on the patient to instigate disclosure of distress and related issues. 
Introducing the DT led to a more systematic approach to identifying distress and informing 
onward referral to appropriate services.  
Despite the acceptability and apparent usefulness of this process in clinical practice; however, 
a key issue is that the validity of the DT for identifying distress in people with IPD has not 
been formally examined in the research literature. This represents an important gap in the 
evidence base. The design of such a study in IPD can be informed by previous validation 
research in other clinical populations. These have used various comparators to assess validity 
against the DT. Although there are examples of studies using both diagnostic schedules and 
other screening tools as comparators – e.g. the Composite International Diagnostic Interview 
(CIDI) (Patel, Sharpe, Thewes, Bell, & Clarke, 2010)  the use of the HADS (Zigmond and 
Snaith, 1983) for comparator analysis against the DT is most common in the literature 
(Campbell et al., 2009; Geest et al., 2018; Zwahlen, Hagenbuch, Carley, Recklitis, & Buchi, 
2008).  
The optimal cut-off range for detecting clinical levels of distress using the DT has typically 
been reported in the literature to be between 3-5 on the 10-point scale (Geest et al., 2018; 
Patel et al., 2010; Wiener, Battles, Zadeh, Widemann, & Pao, 2017). It is not yet known 
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whether a similar score threshold would be suitable in IPD. The PL which accompanies the 
DT has been adapted successfully in order to make it more relevant to specific clinical 
populations (San Giorgi et al., 2017).  In people with recurrent respiratory papillomatosis, the 
adapted PL was found to have excellent overall internal consistency, with several of the 
adapted items predictive of distress in this population e.g. inclusion of speech difficulties. It 
would be of interest to investigate whether a similar relationship is found in IPD.  
Investigating the number and type of problems endorsed on the PL would also  be beneficial 
to the service. It would inform and provide justification for the running of particular groups 
or interventions. For example, if those who rate themselves as being highly distressed also 
tended to endorse a particular type of problem, this may be a potential area to investigate 
further either through gathering qualitative information from people or completion of an 
audit. 
A further consideration is test-retest reliability. It has been suggested in the literature that 
clinician reassurance and empathy may moderate patients’ distress levels (Derksen, Bensing, 
& Lagro-Janssen, 2013). Lower DT ratings after a medical appointment may indicate that the 
DT registers transient distress levels which are likely to resolve after routine consultation 
with a medical professional, and so would speak to its clinical utility in the IPD population 
for streamlining onward referrals to relevant specialist services. The DT has not as yet been 
evidenced to have reliability in this population and so this is an important consideration for 
the current study. This is of particular note as the DT is currently only used prior to the 
person’s consultation which occurs every six to twelve months, and so clinicians need to be 
assured that the DT score is measuring a stable construct. 
Aims 
This study aimed to assess the validity of the DT and associated PL in detecting distress in 
people with IPD. Test retest reliability was also evaluated to assess the stability of the DT 
before and after the medical consultation. Lastly, this study examined the PL to identify its 
usefulness as a potential explanation of participants’ DT scores. The specific research 
questions were as follows:  
Primary research question: 
Is the DT a valid measure to detect distress in patients with IPD?  
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Secondary research questions:  
What is the optimal cut-off point on the DT to accurately classify presence of distress? 
Does the DT have appropriate test retest reliability in IPD patients when measured prior to 
and after a medical appointment relating to their IPD care?  
What are the most common problems endorsed on the MD-PL in this population? 
What is the correlation between the DT score and total number of problems overall?  
What is the correlation between the DT score and number of problems in each separate 
domain?  
Methods 
Participants 
Participants were recruited in NHS Ayrshire and Arran at the Biggart Hospital and Douglas 
Grant Rehabilitation Centre. Inclusion criteria were diagnosis of IPD; registered with a 
Movement Disorder Consultant in the MDC; able to give informed consent; able to 
understand and respond to the study questionnaires (carer/staff may assist with writing if 
necessary); aged 18 years or older. Exclusion criteria: other comorbid neurodegenerative 
diseases (except dementia). Recruitment began on 25th October 2019. As of 16th March 2020, 
all research recruitment was suspended due to the outbreak of COVID-19 and subsequent 
lockdown restrictions. 
Ethical Approval 
This study was approved by the Research and Development Department in NHS Ayrshire 
and Arran (reference number CM/KLB/NM R&D2019AA030; see Appendix K  on page 89) 
and NHS Grampian Research Ethics Committee (reference number 19/NS/0112; see 
Appendix L on page 91). All participants gave written informed consent and relevant data 
protection regulations were followed for the secure storage of study data. 
Measures 
As previously outlined, the DT is an 11-point scale with an associated MD-PL tailored for 
movement disorders (see Appendix M page 94). The HADS (Zigmond & Snaith, 1983) is a 
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self-report measure to assess mood state, which is commonly used in IPD patients and 
is recommended by Scottish Intercollegiate Guideline Network (SIGN) guidelines (2010) as a 
screen for depression in patients with IPD as it has shown to be a reliable measure in people 
with PD (Schrag et al., 2007). It consists of 14 items (7 items on depression and 7 on anxiety) 
with each item rated from 0 to 3 with higher scores indicating elevated distress.  Subscale 
totals for depression and anxiety are calculated separately, with an overall range between 0 
and 21 for each subscale. Scores between 0-7 indicate minimal depression/anxiety, 
scores between 8–10 indicate borderline depression/anxiety and scores of 11 and above meet 
criteria for ‘caseness’, indicating moderate to severe anxiety and/or depression is present.   
A demographic questionnaire (see Appendix N, page 95) was also administered. This 
gathered information on participants’ gender, age, employment and relationship status, as 
well as asking about whether their DT score had changed since their appointment. 
Participants were asked what year they received their diagnosis of PD. 
Procedure 
A PD nurse screened clinic appointment schedules to identify eligible patients and sent out 
the participant information sheet several weeks in advance of their appointment. The DT was 
completed by the patient in the MDC just before their appointment, as is current routine 
practice within the MDC. As part of their consultation, the healthcare professional asked 
eligible patients if they were willing to talk to the researcher about the study. If they 
expressed interest in speaking to the researcher, they were brought to a nearby clinic room 
where any questions were answered. If they consented to take part and signed the consent 
form, they then completed the study questionnaires, with the total time estimated to be 25 
minutes. This entailed completing the DT again (timepoint two), along with the HADS and 
the demographic questionnaire. GP information was obtained and a summary of the research, 
DT and HADS scores was sent to the relevant medical practice. 
Sample size calculation  
A priori power analysis was conducted using G*power 3.1.9.2 (Faul, Erdfelder, Buchner, & 
Lang, 2009) to determine the required sample size. The minimum correlation level was set at 
0.3 based on the estimated correlation between the DT and HADS subscales: 0.51 to 0.56 for 
the anxiety subscale, and 0.36 to 0.69 for the depression subscale (San Giorgi et al., 2017; 
Zwahlen et al., 2008). As the primary research question involved two statistical tests 
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(separately for the depression and anxiety subscales), a Bonferroni correction was applied to 
reduce the likelihood of type 1 error (p-value =0.025). The parameters were: r = 0.3 
(medium), p = 0.025 (two-tailed), power (1-β) = 0.80 (Cohen, 1992). The required sample 
size was determined to be 102 participants. For additional details on expected recruitment 
rates see Appendix O, page 98. 
Statistical Analysis 
Data were analysed using SPSS version 26. Descriptive statistics were used to characterise 
the study sample. To investigate the relationship between the DT and the HADS, Spearman 
correlation analysis was used. Due to the Bonferroni-corrected significance threshold for 
these analyses, the 98% confidence interval (CI) is presented with these correlation estimates 
instead of the usual 95% CI. 
Although this study was not a diagnostic accuracy study, in that distress itself is not a 
diagnosis, a receiver operating characteristic (ROC) curve can be used to identify the optimal 
cut-off point on the DT for capturing clinically significant distress, in line with methods 
outlined by the Standards for reporting of Diagnostic Accuracy Studies (STARD) (Bossuyt et 
al., 2003). Therefore, to answer the second research question, ROC curve analysis was 
planned to assess the classification performance (specificity and sensitivity) for each score on 
the DT against the HADS (score ≥11 versus <11). The graphic display of the curve facilitates 
the selection of an optimal cut-off score for distress for IPD patients. As there is no consensus 
on what constitutes appropriate specificity and sensitivity, Youden’s index was considered to 
establish the cut-off point that maximises both of these domains.  
To determine the test retest reliability of the DT, Spearman correlation coefficient analysis 
was carried out for pre and post appointment scores. Descriptive statistics were reported for 
the number and type of problems endorsed on the MD-PL, pre- and post-appointment. 
Spearman correlations were examined between the DT score and number of problems 
identified by participants, both overall and within each of the seven problem domains.  
Due to the large number of correlations calculated for this research question, Bonferroni 
correction was deemed to be too restrictive, and the false discovery rate (FDR) correction 
was applied instead, to ensure that the proportion of false positives was controlled at 0.05 
across these MD-PL analyses (Benjamini & Hochberg, 1995). The FDR corrections were 
performed using an online calculator (https://www.sdmproject.com/utilities/?show=FDR). As 
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the false positive rate is already controlled in these adjusted p values, the significance 
threshold for each of these results was 0.05 and the 95% CI is reported with the correlation 
estimates.  
Results 
A total of 40 people with a diagnosis of IPD participated in this study; see Appendix P, page 
99, for a flowchart of recruitment. Demographic information for participants is presented 
below in Table 2.1 
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Table 2.1: Demographic characteristics of the sample (N =40). 
 
N % 
Age in years 
  
55-64 7 17.5 
65-74 14 35 
75 or older 19 47.5 
Gender 
  
Male  23 57.5 
Female 17 42.5 
Living arrangements 
  
Alone 10 25 
With family or friend 30 75 
Relationship status 
  
Single 4 10 
Married or have partner 29 72.5 
Widowed 6 15 
Other 1 2.5 
Employment status 
  
Employed/self-employed 3 7.5 
Retired 37 92.5 
 
Descriptive statistics for the DT pre and post appointment and HADS subscales are presented 
in Table 2.2. The HADS anxiety subscale was found to be normally distributed after 
inspection of a scatterplot; however, the HADS depression subscale was non-normally 
distributed. For consistency, the median and quartiles are presented for both. 
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Table 2.2: Descriptive statistics for clinical measures.  
 
Median Percentile 
 
  
25th 75th 
Duration of Parkinson's disease (years) 3.5 1 6 
Distress thermometer pre appt 3.5 1 6 
Distress thermometer post appt 4 1 6 
HADS anxiety 5 3 8 
HADS depression 6 4 10 
 
N % 
 
HADS anxiety caseness 4 10 
 
HADS depression caseness 2 5 
 
HADS = Hospital Anxiety and Depression Scale 
Is the DT a valid measure to detect distress in patients with IPD?  
Spearman’s correlation coefficient was calculated between the DT at time point 2 (post 
appointment) and the HADS subscales. The HADS anxiety subscale demonstrated a large, 
significant correlation of 0.68 with the DT, p = <0.001, 98% CI = 0.38 to 0.85. The HADS 
depression subscale also demonstrated a large, significant correlation of 0.58 with the DT, p 
= <0.001, 98% CI = 0.24 to 0.79.  
However, the sample size recruited for this study was below the amount determined by a 
priori analysis to reliably detect an effect size of 0.30 or higher. Although the estimated 
correlation sizes for the DT with both the HADS anxiety and depression are above .30 in the 
current study, the CIs show that the true correlations could be as low as .38 or .24 
respectively.  
Apriori sensitivity power analysis was conducted using GPower*3 to determine the minimum 
correlation size a sample of 40 would be able to detect reliably. This determined that a 
correlation of 0.46 or higher could reliably be detected by the current study. Given the lower 
bounds of the CIs reported above, it is possible that the true correlations are below 0.46 and 
therefore not reliably detectable by the current study.  
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What is the optimal cut-off point on the DT to accurately classify presence of distress? 
Unfortunately, Apriori sensitivity power analysis using pROC software in R revealed that to 
detect a reasonable balance between sensitivity and specificity i.e. area under the curve =.75, 
the current study was underpowered. This was due to the limited number of participants 
meeting caseness for anxiety (N=4) or depression (N=2) according to the HADS, giving an 
estimated statistical power of only 0.29 for anxiety and 0.15 for depression. For this reason, 
the ROC curve analyses were not undertaken. 
Does the DT have appropriate test retest reliability in IPD patients when measured 
prior to and after a medical appointment relating to their IPD care?  
Spearman’s correlation analysis revealed a very large, significant correlation of 0.98, p 
<0.001, 95% CI = 0.96 to 0.99. The DT scores changed post appointment for eight 
participants. Two participants’ scores decreased by one point whilst the other six increased by 
one to two points. For the two participants whose scores had decreased, both explained that 
they had felt reassured talking about their diagnosis with their PD Nurse.  
For those whose DT score increased post appointment, varied reasons were given. One 
participant noted that seeing all the potential problems written down increased their distress, 
whilst another reported that they were under time pressure after their appointment to get to 
another appointment and so this slightly increased their distress. Another participant reported 
that since filling out the pre-DT, they had thought more about the problems listed and 
identified more, leading to a higher reported level of overall distress. Other reasons for an 
increase in DT scores were most relevant to the emotional domain of the DT problem list and 
involved other issues arising during their appointment regarding limitations of treatment.  
What are the most common problems endorsed on the MD-PL in this population? 
The number of problems endorsed was explored. Median and quartiles for the number of 
problems identified per domain pre and post appointment are displayed below in Table 2.3. 
As can be seen from the table, most problems reported were in the physical and motor 
domains. 
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Table 2.3: Descriptive statistics for Movement Disorder Problem List pre and post 
appointment. 
  
Number of problems 
endorsed 
Number of problems 
endorsed 
 
Domain No. 
problems 
listed 
Pre Percentile 
 
Post Percentile  
  
Median 25th 75th Median 25th 75th 
Physical 22 5 3 6.75 5 3 7 
Motor 8 3 1 4 2.5 1.25 3.75 
Cognitive 6 1 0 2 1 0 2 
Practical 4 0 0 0 0 0 0 
Family 4 0 0 0 0 0 0 
Emotional 7 1 0 2 1 0 2 
Spiritual 3 0 0 0 0 0 0 
Total 54 9.5 6 13 9.5 6 13 
 
Table 2.4 below displays the type of problems endorsed. In the physical domain, the most 
frequently reported problems both pre and post appointment were sleep problems and fatigue; 
sleep problems were endorsed by 65% both pre and post appointment, and fatigue was 
endorsed by 57.5% pre and 55% post.  
In the motor domain the most reported problem was walking, followed by stiffness. There 
were six problems not reported by any of the participants in this study: odd/bizarre behaviour 
(cognitive domain), housing problems (practical domain), problems with relatives/friends 
(family domain), and none of the three problems were endorsed in the spiritual domain. Other 
problems not listed were backache, senses, symptom change and speech impairment. 
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Table 2.4: Types of problems endorsed from the Movement Disorder Problem List. 
Problem List   Pre    Post 
 
N %  N % 
Physical 
  
 
  
Your Appearance 2 5%  3 7.5% 
Bathing or dressing 8 20%  7 17.5% 
Dribbling saliva 11 27.5%  11 27.5% 
Swallowing problems 4 10%  4 10% 
Eating/Appetite 4 10%  7 17.5% 
Change in weight 6 15%  5 12.5% 
Sore/dry mouth 9 22.5%  9 22.5% 
Eating/Appetite 3 7.5%  3 7.5% 
Nausea/Vomiting 3 7.5%  3 7.5% 
Urinary problems 17 42.5%  17 42.5% 
Bowel problems 12 30%  14 35% 
Sleep problems 26 65%  26 65% 
Nightmares 2 5%  3 7.5% 
Acting out in sleep 3 7.5%  3 7.5% 
Need to move legs at night 10 25%  10 25% 
Day time sleepiness 21 52.5%  16 40% 
Fatigue or tiredness 23 57.5%  22 55% 
Swollen legs 8 20%  9 22.5% 
Pain 13 32.5%  13 32.5% 
Sweats 5 12.5%  4 10% 
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Problem List   Pre    Post 
 
N %  N % 
Sexual concerns 2 5%  2 5% 
Taking medication 3 7.5%  4 10% 
Motor 
  
 
  
Tremor 19 47.5%  17 42.5% 
Fine motor control 6 15%  6 15.00% 
Walking 24 60%  22 55.00% 
Stiffness 18 45%  19 47.50% 
Weakness 15 37%  16 40.00% 
Freezing 9 22.5%  10 25.00% 
Bed/Chair mobility 8 20%  8 20.00% 
Falls 6 15%  4 10.00% 
Cognitive 
  
 
  
Memory 13 32.5%  13 32.50% 
Speed of thinking 11 27.5%  12 30.00% 
Concentration and attention 8 20%  7 17.50% 
Judging distance/Space 4 10%  5 12.50% 
Odd/Bizarre behaviour 0 0%  0 0.00% 
Impulsive 4 10%  4 10.00% 
Practical 
  
 
  
Caring responsibilities 2 5.00%  2 5.00% 
Finances, work 2 5.00%  2 5.00% 
Housing 0 0.00%  1 2.50% 
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Problem List   Pre    Post 
 
N %  N % 
Transport/Driving 3 7.50%  3 7.50% 
Family 
  
 
  
Relationship with children 1 2.50%  1 2.50% 
Relationship with partner 1 2.50%  1 2.50% 
Relationship with relatives/Friends 0 0.00%  0 0.00% 
Burden (on family, friends etc) 4 10.00%  4 10.00% 
Emotional 
  
 
  
Sadness or depression 10 25%  11 27.50% 
Loneliness or isolation 5 12.5%  4 10.00% 
Hopelessness 2 5%  2 5.00% 
Worry, fear or anxiety 14 35%  14 35.00% 
Loss of control or freedom 7 17.5%  7 17.50% 
Anger or frustration 9 22.5%  10 25.00% 
Seeing/Hearing things not there 5 12.5%  5 12.50% 
Spiritual 
  
 
  
Spiritual concerns 0 0%  0 0% 
Religious concerns 0 0%  0 0% 
Other spiritual concerns 0 0%  0 0% 
 
What is the correlation between pre and post appointment DT scores with number of 
problems endorsed on the pre and post PL?  
Correlations were calculated between the DT score and the number of problems (overall total, 
and total per domain), both pre and post appointment. Results are displayed below in Table 
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2.5. No problems were endorsed in the spiritual domain and so no correlation could be 
calculated. 
Table 2.5: Correlations between the Distress Thermometer score and number of 
problems endorsed. 
 
Pre 
  
Post 
  
 
Correlation 
(rho) 
FDR 
corrected 
p-value 
95% 
confidence 
interval 
Correlation 
(rho) 
FDR 
corrected 
p-value 
95% 
confidence 
interval 
Physical  0.62 <0.001 0.36 to 0.79 0.61 <0.001 0.34 to 0.79 
Motor 0.64 <0.001 0.38 to 0.80 0.52 <0.001 0.23 to 0.73 
Cognitive 0.21 0.21 -0.11 to 0.49 0.22 0.18 -0.10 to 0.50 
Practical  0.21 0.21 -0.11 to 0.49 0.31 0.07 -0.01 to 0.57 
Family 0.45 <0.001 0.15 to 0.68 0.35 0.04 0.03 to 0.60 
Emotional 0.68 <0.001 0.44 to 0.83 0.57 <0.001 0.29 to 0.76 
Total 0.76 <0.001 0.56 to 0.88 0.71 <0.001 0.48 to 0.85 
FDR = False Discovery Rate 
A similar pattern of correlations was observed both pre and post appointment. The emotional 
domain demonstrated the highest correlation with the DT pre appointment, while the 
cognitive domain showed the lowest correlation with the DT both pre and post appointment. 
These results indicate that interventions targeted at reducing emotional distress for example, 
may be worthwhile as those tending to score higher on the DT also tended to tick problems in 
the emotional domain.  
Similarly, descriptive statistics has already established that the problems most frequently 
endorsed were in the physical and motor domains. The large correlations shown in table 2.5 
indicate that interventions in these areas may be the most promising.  
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Discussion 
This study investigated whether the distress thermometer was a valid screening tool for 
distress in an IPD population. The results indicate the DT may be a valid measure to screen 
for distress in this population. The correlation sizes found in this study are at the larger end of 
those that typically have been found in the literature (San Giorgi et al., 2017; Zwahlen et al., 
2008). This may be due to an over-inflation of the correlation due to the relatively small 
sample size in the current study (discussed further below).  
The present results are in line with the literature in other respects, as the HADS anxiety 
subscale tends to be more highly correlated with the DT than the depression subscale (Geest 
et al., 2018; Gil et al., 2005; Testoni et al., 2018). Although promising, it is important to note 
that the use of the DT as a screening tool should enhance, not replace, clinician judgement 
(Mitchell, 2007). The DT may aid in the identification of distress which may not otherwise 
have been discussed, but it is the clinician who facilitates referral to the appropriate pathway 
of care for the person as required, utilising skilled questioning techniques and decision-
making within the wider multi-disciplinary team.  
As explained above, ROC curve analysis was not performed and so the optimal cut-off point 
to enhance sensitivity and specificity in detecting distress in this study is not known. 
Acceptable test retest reliability results in this study indicate that the DT scores remain 
relatively stable after an appointment related to IPD care, which supports the assumption that 
the DT measures stable, not transient, levels of distress. This is congruent with another study 
in cancer patients, which found a test retest reliability coefficient for the DT of 0.80 after 7-
10 days (Tang, Zhang, Pang, Zhang, & Song, 2011). The larger coefficient found in the 
present study may, again, be due to the modest sample size, or the short duration between the 
two measurements.  
It is important to highlight that three participants stated that their level of distress post 
appointment was itself influenced by being asked to rate their distress.1 This may indicate 
that the DT can have an unintended adverse effect of increasing distress, instead of serving 
 
 
1Distress was raised by one point for each person; this was discussed with all participants and they were aware 
they could contact their GP/MDC clinician if their distress continued. All stated they understood and felt okay 
to leave either alone or with partner/friend. 
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the intended purpose of identifying existing distress in order to provide help. This effect has 
been acknowledged in another UK based study where 5% of 171 participants reported that 
filling out the DT had upset them in some way (Gessler et al., 2008). In another UK study, 
seven out of 598 respondents to a telephone survey using the DT were described as being too 
tearful or upset to answer the question about their level of distress, although it was not stated 
whether this was related to being asked about their distress, or if the individual had been 
upset prior to this (Hughes, Sargeant, & Hawkes, 2011).  
The next research question focused on the problem list pre and post appointment and its 
correlation with the DT score pre and post appointment. The number of problems in the 
physical, motor and emotional domains were highly correlated with the DT. This is a similar 
pattern to what has been found in the literature. A validation study in a sample of people with 
cancer found that the DT score was most highly correlated with the physical  (r =0.64) and 
emotional domains (r=0.61), while other correlations were moderate such as the practical  
(r=0.39), family (r=0.31) and spiritual domains (r=0.26) (Tuinman, Gazendam-Donofrio, & 
Hoekstra-Weebers, 2008). In the present sample only four participants added in problems not 
represented in the MD-PL, so it is likely that the seven PL domains accurately captured the 
main sources of participant distress.   
Strengths and limitations 
This is the first study to validate the use of the DT in the IPD population. A strength of the 
current study is that it explored the PL as well as the overall DT rating of distress, as this is 
not typically explored in similar studies. This makes it a more comprehensive investigation 
into the usefulness of the DT and associated PL in people with IPD. However, the possibility 
of type 1 error in this study is increased as the sample size was underpowered to reliably 
detect a correlation below 0.46. This is a significant limitation of the current study and so all 
results should be interpreted with caution as they may be over inflated and not truly 
representative of the relationships between the variables studied.  
Another limitation is the largely cross-sectional nature of the study (repeated measures 
conducted on the same day), as the sensitivity of the DT in tracking distress over time could 
not be determined by the present study. It could be argued that the use of the HADS as the 
comparator in this study was not ideal, as the HADS is itself a self-report screen. However, 
using more detailed diagnostic schedules such as the CIDI or DSM criteria to assess construct 
validity would not be appropriate here, as this study did not set out to identify clinical 
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disorders, and this is not what the DT is used for in routine clinical practice in this setting. A 
third limitation is the design of the study for assessing test retest reliability. DTs were 
completed over a short space of time, before and after their appointment. This design can 
only demonstrate whether or not the DT is stable pre and post appointment, not over a longer 
period of time. Other studies validating the DT typically assesses distress over a longer time 
period, such as week. This design would have allowed for an increased level of confidence in 
the reliability of the DT in people with IPD, over time. As the DT measures distress over the 
past week, this design is appropriate. Assessing distress using the DT immediately post 
appointment and one week post appointment would allow for stability over time to be 
assessed, in the absence of clinical influence. Although it was not feasible given the time 
constraints of the current study, this is an area for future research to consider a longer period 
between timepoints. 
Future directions 
The results of this study provide a basis for future research to replicate these findings using a 
larger sample. This would allow for more robust conclusions to be drawn. This is an 
important area because, as previously mentioned, the NICE guidelines recommend the DT to 
be used to screen for distress in chronic conditions (NICE, 2009).  Further research in this 
population would therefore usefully inform these guidelines. The validity of the DT in other 
Parkinsonian disorders such as progressive supranuclear palsy, and other movement disorders 
should also be evaluated. 
Conclusion 
The DT shows promise and relevance as a screening tool for distress in individuals with IPD; 
however, replication of these results is needed in a larger sample to determine reliability and 
generalisability beyond that of the current study. 
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Chapter 3: Appendices 
Appendix A. Author guidelines for submission to Movement Disorders 
Journal 
Form of Manuscripts 
Pages should be numbered in succession, the title page being number one. 
The text of the manuscript should be in the following sequence: 
(1) Title page: 
The opening page of each manuscript should include: 
(a) article title (no abbreviations/acronyms).Titles should be short, specific and clear. They 
should not exceed 100 characters. Do not use abbreviations/acronyms in the title; 
(b) authors' names, degrees, and affiliations (indicate the specific affiliation of each author by 
superscript, Arabic numerals); 
(c) name, address, telephone and email address of the corresponding author; 
(d) word count; 
(e) a running title not exceeding 45 letters and spaces; 
(f) Key words – up to 5; 
(g) Financial Disclosure/Conflict of Interest concerning the research related to the 
manuscript: All information on support and financial issues from all authors relative to the 
research covered in the submitted manuscript must be disclosed regardless of date. Other 
financial information unrelated to the current research covering the past year will be 
documented at the end of the manuscript (see below). 
(h) Funding sources for study. 
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(2) Abstract 
Structured Abstract: We require that authors submit structured abstracts. The page following 
the title page of Full-Length Articles should include an abstract of up to 250 words. The 
abstract should be structured. The page following the title page of a Brief Report should 
include a structured abstract of up to 150 words. Reviews should include an unstructured 
abstract. Viewpoints do not need any abstract. 
(3) Introduction 
Give a brief description of the background and relevance of the scientific contribution. 
(4) Methods 
Describe the methodology of the study. For experimental investigation of human or animal 
subjects, please state in this section that an appropriate institutional review board approved 
the project. For those investigators who do not have formal ethics review committees, the 
principles outlined in the “Declaration of Helsinki” should be followed. For investigations in 
human subjects, state in this section the manner in which informed consent was obtained 
from the subjects. A letter of consent must accompany all photographs, patient descriptions, 
and pedigrees in which a possibility of identification exists. The authors are responsible for 
ensuring anonymity.  
(5) Results 
No specific regulations.  
(6) Discussion 
No specific regulations. 
(7) Acknowledgment 
No specific regulations. These may be published online at the discretion of the editor. 
(8) Authors' Roles 
List all authors along with their specific roles in the project and preparation of the 
manuscript. 
These may include but are not restricted to: 
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1) Research project: A. Conception, B. Organization, C. Execution; 
2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 
3) Manuscript: A. Writing of the first draft, B. Review and Critique. 
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Appendix B. Ten steps for conducting a systematic review of PROMS 
(Reprinted from with permission from the COSMIN manual  (Mokkink et 
al., 2018). 
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Appendix C. Modifications made to COSMIN guidance 
Steps followed are in red. 
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Appendix D Additional modifications made to COSMIN guidance 
• COSMIN do not prescribe a column to report both subscales and summary index 
metrics for internal consistency and reliability; however, they recommend that if there 
are doubts about the potential multidimensionality of the instrument, the summary 
index number should not be used. As there are queries in the literature about the 
unidimensionality of all instruments included in this review, apart from the 
Parkinson’s Impact Scale, which was designed to be multidimensional, it was decided 
that displaying both subscale and summary index figures would aid transparency 
when considering the psychometric properties of instruments. 
 
• COSMIN guidance states that for construct validity, it is enough to report whether 
hypotheses for construct validity have been met. In results table 2, this was expanded 
upon to include the name of the instrument that was used as comparator and whether 
discriminant or convergent validity had been assessed.  
 
• Regarding discriminant validity, the results tables templates provided by COSMIN do 
not include this; however, the risk of bias ratings do provide a specific column for 
discriminant validity. Therefore, it was decided to include this information in the 
results table to enable a more comprehensive review of each instrument. To balance 
transparency with following COSMIN guidance, the risk of bias rating for 
discriminant validity are displayed in table 2 but the specific metrics are not (e.g. 
correlations or means and standard deviations). Most studies included for review used 
p-value statistics to calculate discriminant validity. COSMIN guidance states that p-
values are not an appropriate method of assessing this construct as it is not important 
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to know whether the figures are significantly different from zero (Mokkink et al., 
2018). To prevent unfair or misleading risk of bias ratings; however, it was decided 
that if studies reported the figures i.e. the mean and standard deviations as well as the 
p-value, the risk of bias rating would be A to indicate ‘adequate’. 
 
• COSMIN incorporates the Grading of Recommendations, Assessment, Development, 
and Evaluation (GRADE) approach to synthesise the evidence across studies. This 
was deemed unnecessary for the purposes of the current review as studies included 
were not predicted to be homogeneous given the varied languages and cultures across 
studies. It would therefore be unsuitable to collate these studies and assign an overall 
quality rating per measurement property. 
 
• Two characteristics noted by COSMIN (PROM development and content validity) 
were not necessary to evaluate for the present review, as these apply to newly 
developed instruments. Content validity has been established in all instruments 
reviewed. 
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Appendix E. Screenshot of search terms in EBSCOhost database. 
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Appendix F. Risk of bias procedure. 
Reprinted with permission from COMSIN (Mokkink et al., 2018). 
3.1.1 Evaluating the methodological quality of studies 
To evaluate the methodological quality of the included studies using the COSMIN Risk of 
Bias checklist, it should first be determined which measurement properties are assessed 
in each article. The methods used in each study to produce the results for a given 
measurement property were evaluated to identify risk of bias. 
Determine which measurement properties are assessed 
Often multiple studies on different measurement properties are described in one article 
(i.e. one study for each measurement property, e.g. a study on internal consistency, 
construct validity, and reliability, each with its own specific design requirements). The 
quality of each study is separately evaluated using the corresponding COSMIN box 
(Table 3). The COSMIN Risk of Bias checklist should be used as a modular tool; only 
those boxes should be completed for the measurement properties that are evaluated in 
the article. 
Table 3. Boxes of the COSMIN Risk of Bias checklist 
Mark the measurement properties that have been evaluated in the article*. 
Content validity 
Box 1. PROM development 
Box 2. Content validity 
Internal structure 
Box 3. Structural validity 
Box 4. Internal consistency 
Box 5. Cross‐cultural validity\measurement invariance 
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Remaining measurement properties 
Box 6. Reliability 
Box 7. Measurement error 
Box 8. Criterion validity 
Box 9. Hypotheses testing for construct validity 
Box 10. Responsiveness 
* If a box needs to be completed more than once two or more marks can be placed. 
Sometimes the same measurement property is reported for multiple (sub)groups in one 
article. For example, when an instrument is validated in two different countries and the 
measurement properties are reported for both countries separately. In that case, the 
same box may need to be completed multiple times if the design of the study was 
different among countries. The review team should decide which boxes should be 
completed (and how many times).An example of one question asked to determine risk of bias 
for structural validity is given below: 
Statistical methods  
1 For CTT: Was exploratory or 
confirmatory factor analysis 
performed? 
Very good  Adequate Doubtful Inadequate N/A 
Confirmatory 
factor analysis 
performed 
 
Exploratory 
factor analysis 
performed 
 No exploratory 
or confirmatory 
analysis 
performed 
Not applicable 
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Appendix G. Descriptions of each measure included for review 
EuroQol/EQ-5D  
The EQ-5D is a self-report measure of generic HRQoL originally developed in 1990 (Brooks 
& EuroQol, 1996). It consists of five dimensions—mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension has three levels which are rated by 
the individual (no problem; some problem; extreme problem). These levels have since been 
expanded to five levels to prevent against ceiling effects for ratings (EQ-5D-5L). In addition, 
individuals are also asked to rate their health status on a 100-point visual analogue scale, with 
higher scores indicating higher HRQoL. 
Parkinson’s Disease Questionnaire-39 (PDQ-39) 
The PDQ-39 is a 39-item self-report questionnaire which assess the HRQoL of people with 
PD. It was originally developed in 1995 and has eight separate subscales/domains including: 
Mobility, Activities of Daily Living, Emotional Well-Being, Stigma, Social Support, 
Cognitions, Communication and Bodily Discomfort (Jenkinson, Fitzpatrick, Peto, Greenhall, 
& Hyman, 1997). People are asked to respond to these 39 questions in relation to who they 
have felt over the past four weeks. Individual items are rated on a four-point Likert scale with 
higher scores representing worse HRQoL. 
Parkinson’s Disease Questionnaire-8 (PDQ-8) 
The PDQ-8 was developed as a briefer version of the PDQ-39 and also asks for ratings of 
HRQoL over the past four weeks (Jenkinson et al., 1997). Individuals answer eight questions, 
one from each of the domains mentioned above for the PDQ-39. Several studies in this 
review utilised the PDQ-8/39 (nested in the PDQ-39). The PDQ-39 is given to participants 
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with eight questions highlighted to answer, rather than the PDQ-8 being presented as a 
separate questionnaire.  
Parkinson’s Disease Quality of Life Scale (PDQL)  
The PDQL is a Parkinson’s Disease specific HRQoL measure consisting of four subscales : 
parkinsonian symptoms (14 items), systemic symptoms (seven items), social function (seven 
items), and emotional function (nine items) (de Boer, Wijker, Speelman, & de Haes, 1996).  
This scale has a total of 37 items with higher scores indicating better HRQoL. It was 
originally developed in the Dutch language. All studies included in this review utilised the 
English version of the PDQL as a template for further translation. 
Parkinson’s Impact Measure Scale (PIMS)  
The PIMS is a multi-dimensional self-report PD specify HRQoL measure which consists of 
10 items (Calne et al., 1996). It was originally developed for use with individuals with a 
diagnosis of idiopathic PD. The items in the PIMS reflect broader domains of emotional, 
social and economic issues for the individual. Higher scores reflect lower HRQoL. 
Individuals whose PD symptoms are stable only score each item once, whereas those with 
fluctuations in symptoms judge the negative impact for both 'on' and 'off' periods. Broadly 
speaking  ‘on’ refers to times when they are functioning at their best and ‘off’ when they are 
functioning at their worst. The scale contains two optional items (sexuality and financial 
security). 
Scales for Outcomes - Psychosocial (SCOPA-PS) 
The SCOPA-PS is an 11-item self-report instrument which assesses psychosocial functioning 
over the previous month (Marinus, Visser, Martı́nez-Martı́n, van Hilten, & Stiggelbout, 
2003). Each item has four-point response rating scale (0-3). Higher scores indicate worse 
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psychosocial functioning. It focuses on areas of social activities, emotions and contact with 
others It was originally developed in the Dutch language. All studies included in this review 
used the English language version of the SCOPA-PS as a template. 
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Appendix H. Breakdown of instruments by language  
Language breakdown for each 
instrument 
  
Language Instrument Reference 
Spanish 
  
 
PDQ-39 (Martinez-Martin, 
Serrano-Duenas, & 
Vaca-Baquero, 2005)  
PDQ-8/39 (Jenkinson & Fitzpatrick, 
2006)  
PDQL (Serrano-Dueñas, 
Martı́nez-Martı́n, & 
Vaca-Baquero, 2004)  
PIMS (Serrano-Dueñas & 
Serrano, 2007) 
(Local Spanish of Argentina 
and Ecuador) 
SCOPA-PS (Virués-Ortega et al., 
2009)   
(Martinez-Martin et al., 
2009) 
Persian  
  
 
PDQ-39 (Nojomi, Mostafavian, 
Shahidi, & Jenkinson, 
2010)  
SCOPA-PS (Fereshtehnejad et al., 
2014) 
Chinese 
  
 
PDQ-39 (Luo, Tan, Li, Soh, & 
Thumboo, 2005) 
(Taiwan) 
 
(Ma, Hwang, & Chen-
Sea, 2005)   
(Luo et al., 2010)   
(Zhang & Chan, 2012)  
PDQ-8 (Huang, Hsu, Wang, & 
Chen, 2011)  
EQ-5D (Luo, Low, Lau, Au, & 
Tan, 2009)    
 
PDQ-8 (Tan, Lau, Au, & Luo, 
2007)  
PDQ-8/39 (Chen et al., 2017) 
Serbian 
  
 
PDQ-39 (Žiropađa, Stefanova, 
Potrebić, & Kostić, 
2009) 
Korean 
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PDQ-39 (Kwon et al., 2013)   
(Park, Sohng, & Kim, 
2014) 
Filipino 
  
 
PDQ-39 (Suratos, Saranza, 
Sumalapao, & Jamora, 
2018)    
Italian 
  
 
PDQ-39 (Galeoto et al., 2018)  
PDQ-8 (data pooled with 
PDQ 8/39) 
(Franchignoni, Giordano, 
& Ferriero, 2008)  
PDQ-8/39 (Jenkinson & Fitzpatrick, 
2006) 
Greek 
  
 
PDQ-8 (Katsarou et al., 2004) 
Turkish 
  
 
PDQ-8 (Kahraman et al., 2018)  
PDQL (Dereli et al., 2015) 
Japanese 
  
 
PDQ-8/39 (Jenkinson & Fitzpatrick, 
2006) 
Portuguese 
  
 
PDQ-39 (Carod‐Artal, Martinez‐
Martin, & Vargas, 2007)   
(Jesus-Ribeiro, Vieira, 
Ferreira, Januário, & 
Freire, 2017)  
PDQL (Campos et al., 2011) 
  (Jesus-Ribeiro et al., 
2017)  
SCOPA-PS (Carod‐Artal et al., 2007)   
(Virués-Ortega et al., 
2009) 
Guarani 
  
 
SCOPA-PS (Virués-Ortega et al., 
2009) 
German 
  
 
SCOPA-PS (Knudsen, Martinez-
Martin, & Deuschl, 
2007) 
French 
  
 
SCOPA-PS (Soulas et al., 2016) 
Dutch 
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PDQ-39 (Marinus, Visser, 
Jenkinson, & 
Stiggelbout, 2007) 
Bulgarian 
  
 
PIMS 
 
  
(Todorova & 
Stambolieva, 2007) 
Estonian 
  
 PDQ-39 (Krikmann, Taba, Lai, & 
Asser, 2008) 
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Appendix I.  Risk of bias additional information by measurement property 
Structural validity: Five studies were deemed inadequate based on sample size, i.e. they did 
not have seven times the number of items in the instrument as specified by COSMIN. Six 
were rated as doubtful due to uncertainties about sample size included for factor analysis in 
the paper, and lack of clarity about which rotation method was used. 
Reliability: COSMIN guidance of at least 2 weeks/14 days between first and second 
administration of an instrument was followed. In addition, many HRQoL measures such as 
the PDQ-39 were designed to measure HRQoL in the past month. Therefore, the time limit 
for this review deemed ‘very good’ was between 2-4 weeks.     
There were 12 data points for reliability which were rated as ‘inadequate’. Reasons for this 
were a change of environment between administrations, typically this was reported when an 
instrument was self-administered at home as opposed to the clinic/hospital. This may 
therefore result in increased missing data and different responses than the original 
questionnaire as unlike in the clinic/hospital setting, any participant queries cannot be 
clarified by a health care professional. Another reason was the length of time between 
administrations which typically was reported as being less than 14 days for some papers. 
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Appendix J. Author guidelines for submission to the Parkinson’s Disease 
Journal 
 
Research Reports 
Organization and style of presentation 
Manuscripts must be written in US English. Authors whose native language is not English are 
recommended to seek the advice of a native English speaker or English language service 
before submitting their manuscripts. A language or editing service that we recommend 
is PeerWith. 
Manuscripts should be double spaced throughout with wide margins (2.5cm or 1in), including 
the abstract and references. Every page of the manuscript, including the title page, references, 
tables, etc., should include a page number centered at the bottom. 
Manuscripts should be organized in the following order with headings and subheadings typed 
on a separate line, without indentation.  
Title Page 
1. Title (should be clear, descriptive and concise). 
2. Full name(s) of author(s). 
3. Full affiliation(s). Delineate affiliations with lowercase letters. 
4. Present address of author(s), if different from affiliation. 
5. Running title (45 characters or less, including spaces). 
6. Complete correspondence address, including telephone number, fax number and e-mail 
address. 
Leave the author information blank if double-blind peer review is wished for, but do include 
the information in the submission letter to the editor. 
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Abstract and Keywords 
The abstract for research papers should follow the “structured abstract” format: 
BACKGROUND: 
OBJECTIVE: 
METHODS: 
RESULTS: 
CONCLUSIONS: 
The abstract should try to be no longer than 250 words.  
For other papers such as Reviews, the abstract should be clear, descriptive, and self-
explanatory, and no longer than 250 words. 
Include a list of 4-10 keywords. These keywords should be terms from the MeSH database. 
Introduction 
Materials and Methods 
There is no word limit to the materials and methods section, as the journal’s policy is that 
methodological rigour and reproducibility is of great importance. 
Results 
Discussion 
Acknowledgments including sources of support 
Conflict of Interest 
If there is no conflict of interest to declare, do still include this section and insert “The 
authors have no conflict of interest to report”. 
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Appendix K. Copy of R&D approval  
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Email from R&D dated 20.02.20 
 Dear Bronagh 
 
2019AA030 Validation of the Distress Thermometer with People with Parkinson’s 
Disease 
I have received the documents below relating to a minor amendment to the above study:  
▪ Notification of Non Substantial Amendment  
▪ Sponsor Confirmation 
▪ Samantha Ross CV 
 
I can confirm that the above amendment has been acknowledged and given continued R&D 
permission.  
I can also confirm that Samantha Ross has now been added as an investigator for the study. 
A letter is no longer issued for non-substantial amendments. Please retain this email for your 
records. 
 
Kind regards 
Colin Irving 
R&D Assistant 
NHS Ayrshire & Arran 
Research & Development  
56A Lister Street 
University Hospital Crosshouse  
Kilmarnock 
KA2 0BE 
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Appendix L. Ethics approval letter 
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Appendix M. Distress Thermometer and problem list. 
 
IRAS Project ID 262666                                                                                                            V1    10.06.19                                         
Participant ID:                                                                                                                              Pre/Post: 
Date completed: 
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Appendix N. Additional Questionnaire 
All questions are optional. Not answering these questions will not 
affect your participation in the study. 
 
 
Q1. Age 
1. 18-34 years old 
 
2. 35-44 years old 
 
3. 45-54 years old 
 
4. 55-64 years old 
 
5. 65-74 years old 
 
6. 75 years or older 
  
 
Q2. Gender 
1. Male 
 
2. Female 
 
3. Other 
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PLEASE TURN OVER 
 
Q3. Relationship status 
 
1. Single  
 
 
2. Married/partner/cohabiting 
 
 
3.       Widowed  
 
 
4.       Other 
  
 
 
 
 
Q4. Living arrangements 
 
1. Alone 
 
 
2. With family/friend 
 
 
3. Supported/sheltered accommodation 
 
 
4.    Nursing/care home 
  
 
 
 
   Q5. Employment status 
 
1. Employed/self-employed 
 
 
2. Retired 
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3.   Unemployed 
  
 
PLEASE TURN OVER 
 
Q6a. Is your Distress Thermometer score after the clinic appointment different from 
your Distress Thermometer score before the clinic appointment?  
 
 
1. Yes  
 
 
 
2. No 
 
 
3. Not sure 
 
 
 
Q6b. If yes, can you give us some information about why the score has changed? 
Please write your answer in the box.   
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Appendix O. Additional information regarding recruitment. 
 
A discussion with staff including Psychiatry at the Movement Disorder Clinic revealed that 
there are approximately 600 people are diagnosed with PD in Ayrshire and Arran with 208 
patients on regular review in South Ayrshire MDC. The majority of these diagnoses were 
IPD and would therefore meet the study eligibility criteria. It was estimated by MDC that 
during the planned 12-month recruitment period, 208 patients would have scheduled 
appointments. Given the low DNA (12%) rate recorded at the clinic, the required sample size 
was therefore thought to be feasible for this study. 
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Appendix P. Flowchart of recruitment 
  
Number of information sheets sent 
N=67 
Number of people who agreed to 
speak to researcher  
N=42 
Total number who participated in 
study N=40 
Number of people who declined to 
take part after discussion with 
researcher N=2 
Reasons given: 
Individual believed it was a different 
research project, as they had been 
sent fliers for other research n=1 
Individual wished to speak to their 
GP before taking part in research 
n=1 
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Appendix Q. Major Research Project Protocol 
Validation of the Distress Thermometer with People with Parkinson’s Disease 
27th May 2019 
Version: V3 
Abstract 
Background. The Distress Thermometer (DT) was developed as a tool to detect 
distress in prostate cancer patients and has since been validated in various medical conditions 
and age groups. Idiopathic Parkinson’s disease (IPD) is a progressive neurological condition 
that causes a variety of motor symptoms (such as tremor, rigidity, and slowness of 
movement) and non-motor symptoms including cognitive and mood disorders, nerve pain, 
and sleep disturbances. To date, no studies have assessed the success of the DT at detecting 
distress in this population. Aims. The primary aim of the proposed study is to determine if the 
DT is a valid measure to detect distress in patients with IPD. Method. This is a prospective 
observational study. Participants with IPD will be recruited from the Movement Disorder 
Clinic in NHS Ayrshire & Arran. The DT will be administered with the Hospital Anxiety and 
Depression Scale used as a comparator. To assess test-retest reliability of the DT, this will be 
measured before and after clinic appointment. Applications. If the DT is found to be a valid 
measure to detect distress in people with IPD it may encourage clinicians to use DT to assess 
distress in this population in a busy clinical setting.  
Introduction 
Distress is a multi-faceted concept pertaining to a negative or unpleasant experience which 
may be psychological (i.e. cognitive, behavioural, emotional), social, and/or spiritual in 
nature (Holland & Bultz, 2007). It is documented in the literature as impacting negatively on 
103 
 
medical patients’ quality of life and can act as a barrier to seeking appropriate treatment 
(Ransom, Jacobson & Booth-Jones, 2006).  
The importance of screening for distress in medical populations is also documented in the 
literature (Donovan et al., 2014) and is currently assessed for as part of routine clinical 
practice for many physical health conditions.  
One commonly used measure is the Distress Thermometer (DT), developed by Roth et al. 
(1998). The DT is a visual analogue scale ranging from 0-10 with individuals asked to 
indicate which number best represents their levels of distress in the past week, with 0 
indicating no distress and 10 indicating extreme distress. After rating their overall distress 
level, patients are then asked to indicate the source of this distress under domains including 
practical, family and/or emotional problems, by completing the accompanying problem list 
(PL). Although the DT has been assessed as a valuable tool in various clinical populations, it 
is used in populations which have not yet validated the DT as being a suitable screening tool.  
Idiopathic Parkinson’s disease (IPD) is a progressive neurological condition that causes a 
variety of specific motor symptoms and non-motor symptoms (Park & Stacy 2009). In people 
with IPD, psychological distress including anxiety and depression has been shown to be 
under reported in this population and to impact negatively on quality of life (e. g. Chen & 
Marsh, 2014). Impairments in instrumental activities of daily living such as driving and 
ability to manage finances are also associated with IPD (Martin et al., 2013) and may result in 
elevated distress levels.  
The Movement Disorders Clinic (MDC) in NHS Ayrshire & Arran (NHSA&A) introduced 
the DT with an adapted problem list (MD-PL) (Appendix A) in 2017. Prior to the 
introduction of the DT, distress was not routinely enquired about in MDCs, with the onus on 
the patient to divulge issues related to distress. The DT has been deemed to be a useful brief 
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screening tool for use in busy clinical settings (Snowden et al., 2011) for a variety of cancers 
and clinical conditions across the lifespan; however, in an IPD population which has a 
different genesis and trajectory, its utility for identifying distress has not yet been established.  
Validation studies of the DT in other clinical populations have used various comparators to 
assess validity. Although there are examples of studies using a screening tool as the 
comparator, along with a diagnostic tool e.g. the Composite International Diagnostic 
Interview (CIDI) used by Patel et al (2011); using the Hospital Anxiety and Depression Scale 
(HADS) (Zigmond and Snaith, 1983) alone for comparator analysis against the DT is 
common in the literature (Zwahlen et al., 2008; San Giorgi et al., 2016; van der Geest et al., 
2018; Campbell et al., 2009). There are also studies using the HADS or alternative screening 
tools such as The Patient Health Questionnaire–9, to assess for affective syndromes 
specifically (e.g. Hegel et al., 2008); however, the HADS is typically used as comparator of 
the DT to compare it as a useful tool to detect psychosocial and physical distress more 
generally.  
Using a tool such as the CIDI or DSM criteria to assess construct validity would not be 
appropriate in the current study as the primary aim is not to identify clinical disorders using 
the DT in an IPD population. However, it may be useful to examine classification accuracy 
against the caseness threshold on the HADS, as a secondary objective. Although this study is 
not a diagnostic accuracy study, in that distress itself is not a diagnosis, a receiver operating 
characteristics (ROC) curve can be used to identify the optimal cut-off point on the DT for 
capturing clinically significant distress (HADS caseness), maximising both sensitivity and 
specificity, in line with methods outlined by the Standards for reporting of Diagnostic 
Accuracy Studies (STARD) (Bossuyt et al., 2003).  
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Currently, patients are asked to complete the DT before their consultation appointment at the 
MDC. After their consultation, it is possible that some patients may be reassured about their 
difficulties and this may be reflected in repeated DT scores. This possibility will be 
investigated in the proposed study by administering the DT both before and after the patients’ 
appointment at the MDC. If distress levels are lowered after the appointment, this may 
indicate that the DT registers transient distress levels which are likely to resolve after routine 
consultation with a medical professional. 
Lastly, the proposed study will examine the problem list to identify its usefulness as a 
potential explanation of participants’ DT scores. 
Aims and Hypotheses 
The main aim of this study is to examine whether the ultra-short screen, the DT, is a valid 
measure to assess distress in an IPD population against another screening tool, the HADS. 
Primary research question: 
• Is the distress thermometer a valid measure to detect distress in patients with 
Idiopathic Parkinson’s Disease?  
Secondary research questions:  
• What is the optimal cut-off point on the DT to accurately classify presence of distress? 
• Does the DT have appropriate test re-test reliability in IPD patients when measured 
prior to and after a medical appointment relating to their IPD care?  
• What are the most common problems endorsed on the MD-PL in this population? 
• What is the correlation between the DT score and total number of problems overall?  
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• What is the correlation between the DT score and number of problems in each separate 
domain?  
 
Hypotheses for primary research question 
In line with other studies the primary research hypothesis will be based on the correlation 
between the DT and the HADS. 
H0: The DT will not demonstrate appropriate construct validity to detect distress in IPD 
patients when the HADS is used as comparator. Specifically, the correlation coefficient will 
not be reliably different from zero, so that the 95% confidence interval will include zero. 
H1: The DT will demonstrate appropriate construct validity to detect distress in IPD patients 
when the HADS is used a comparator. Specifically, the DT score will have a positive 
correlation with either the HADS anxiety or depression score. Furthermore, a correlation 
coefficient of 0.3 or higher will be interpreted as clinically meaningful. 
Plan of Investigation 
Participants 
Patients with IPD will be recruited from the NHSA&A MDC.  
Inclusion and Exclusion criteria  
Inclusion criteria: Diagnosis of Idiopathic Parkinson’s Disease; registered with a Movement 
Disorder Consultant in the Movement Disorders Clinic; able to give informed consent; able 
to understand and respond to the study questionnaires (carer/staff may assist with writing if 
necessary); aged 18 years or older.  
Exclusion criteria: Other comorbid neurodegenerative diseases. 
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Recruitment Procedures 
See Research Procedures section below. 
Measures  
Distress Thermometer & Movement Disorder Problem List  
See appendix A. The adapted PL was developed in consultation with the MD Consultant, 
Community Nurse Specialists, Pharmacy and Clinical Psychologists. 
Hospital Anxiety and Depression Scale  
The DT thermometer will be validated using a licensed version of the HADS. The HADS is a 
commonly used self-report measure and is recommended by SIGN guidelines (2010) as a 
screen for depression in patients with IPD and has demonstrated good internal reliability and 
validity (Bjelland et al., 2002). The HADS consists of 14 items (7 Depression and 7 Anxiety) 
each rated from 0 to 3 with higher scores indicating increased severity. Subscale totals are 
calculated, and an individual can score between 0 and 21 for either subscale. Scores of 11 and 
above indicate depression/anxiety is present. 
Additional Information 
A brief questionnaire asking for information on employment status, marital status, and 
feedback on their DT responses. Consent will also be obtained to gather other routine clinical 
information such as age and clinical history from medical records. 
Design  
Prospective observational study. 
Research Procedures 
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Relevant professionals will be approached to be involved in the research to identify potential 
participants. A participant information sheet with details of the study will be sent out to 
potential participants several weeks in advance of their appointment. The DT (time point one) 
will be filled out in the reception area of the MDC prior to their appointment, as is current 
practice within the MDC.  
As part of their consultation the medical professional will again inform them of the study and 
ask if they are willing to participate. Prior to the introduction of the DT in the MDC, distress 
was not routinely enquired about, and so all eligible participants will be asked to take part in 
the study regardless of DT and PL responses or clinical discussions during their 
appointments. If they wish to take part, the researcher will take them to a pre-booked room in 
the clinic to complete questionnaires with the total time estimated to be 25 minutes. Once 
participants have read through the participant information sheet again if they wish to do so, 
and signed the consent form, they will then be asked to fill out the DT again (time point two), 
and the HADS . They will then be asked to complete a brief questionnaire to collect 
additional information.  
If participants are unable to complete the questionnaires immediately after their appointment, 
the consent form will be signed in clinic and participants will be given the measures to 
complete in a pre-paid postage envelope. An arrangement will be made to phone them within 
two working days to check if they have any queries about completing them. Due to the 
timescale required for assessing test retest reliability of the DT, for those whom a phone call 
is not feasible due to speech impairment/do not have a telephone in their home, a home visit 
within two working days will be arranged. If participants complete the DT at a later date, for 
example, at home after the clinic, this will be addressed as a limitation of the study in 
assessing test retest reliability of the DT. This is due to the possibility that other variables 
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have interacted with the participant’s distress levels apart from clinician assurance, with the 
risk of this increasing if participants do not complete time point two DT at the clinic. 
Data from these measures will be collated onto an SPSS database on the University network. 
Information on this database will only be available to the Trainee Clinical Psychologist and 
Chief Investigator conducting the research and will be retained until the study is completion 
and submission to a scientific publication has been approved. No identifiable participant 
information will be entered onto this database. Participants will be identified using an ID 
number, which will be stored separately from research data in a locked filing cabinet in NHS 
Ayrshire and Arran. These will only be accessible to the Trainee who is conducting the 
research and will be stored until the study is completion and summaries of the results have 
been sent to those who opted in to receive this. 
Data Analysis 
Descriptive statistics will be used to describe the study sample. Primary aim: To investigate 
the relationship between DT and the HADS (both completed after the medical consultation), 
Spearman correlation coefficient analysis will be used. 
Secondary aims: Receiver operating characteristic (ROC) curve analysis will be conducted to 
assess the classification performance (specificity and sensitivity) for each score on the DT 
with the HADS (score ≥11 versus <11) used for comparison. The graphic display of the curve 
will facilitate the selection of an optimal cut-off score for distress for IPD patients. There is 
no consensus in the literature as to what constitutes ‘good’ specificity and sensitivity, as this 
depends on the clinical purpose of the screen. Youden’s index is used to find the cut-off that 
maximises both sensitivity and specificity, and so this is how the optimum cut-off point will 
be identified (Akobeng, 2007). 
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To determine the test retest reliability of the DT, correlation coefficient analysis will be 
carried out between time point one (before appointment) and time point two (after 
appointment).  
Descriptive statistics for the number and type of problems endorsed on the MD-PL, both 
before and after the appointment will be reported. Correlations between DT score and number 
of problems identified by participants will be examined. Due to the large number of 
correlations , False Discovery Rate (FDR) corrections will be applied to the p values, to 
ensure that the proportion of false positives is controlled at 0.05 within the analyses for each 
separate research question (Benjamini & Hochberg, 1995). 
Exploratory multiple regression models between problems and DT score, adjusting for 
demographic and clinical covariates, will be conducted if the final sample size permits this.  
Justification of sample size 
Apriori power analysis was conducted using G*power 3.1.9.2 (Faul et 
al.,2009) to determine the required sample size. Analysis was based on the estimated 
correlation between the DT and HADS measures. Parameters: r = 0.3 (medium), p =0.025 
(two-tailed; Bonferroni adjustment because HADS anxiety and depression will be analysed 
separately), power (1-β) = 0.80 (Cohen, 1992). The rationale for choosing 0.3 as the 
estimated effect size is based on results from previous studies which found correlations for 
anxiety subscales ranging from 0.51 to 0.56, and depression subscales from 0.36 to 0.69 
(San Giorgi et al., 2017; Zwahlen et al., 2008). Furthermore, a correlation of less than 0.3 
would likely be clinically negligible.  
Sample size was determined to be 102 participants. Approximately 600 people are diagnosed 
with PD in Ayrshire and Arran with 208 patients on regular review in South Ayrshire MDC. 
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It is estimated that during the 12-month recruitment period, 208 patients will be attending the 
MDC. 
Currently, the two largest MDC clinics take place on Monday morning and Friday mornings 
which, given the primary researchers’ University currently allocated timetable, will allow for 
data collection on these days. The non- attendance (DNA) rate at the clinics was estimated to 
be 12% by clinician’s who are part of the MDC and who are facilitating the proposed 
research. Given the low DNA rate recorded at the clinic, the required sample size was 
therefore deemed to be feasible for the proposed study.  
At three months into recruitment, participant numbers thus far will be evaluated. If this falls 
significantly below what would be expected at this time point (i.e. 102 x 0.25 = 26), the 
primary researcher will liaise with their clinical practice placement at that time to facilitate 
their attendance at more clinics in order to increase recruitment numbers.  
Settings and Equipment 
The MDC will be the primary setting for the proposed research. A room will be booked out to 
allow for completion of measures. 
Dissemination of results 
Results will be disseminated through scientific publication, conference presentations and the 
dissertation arising from this research. As noted on the consent form, participants can opt-in 
to receive a summary of the results from the study if they wish to do so. 
Health and Safety Issues 
Researcher safety issues 
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Home visits will be conducted as necessary and both the Lone Working Policy provided by 
NHS A&A will be followed and the Lone Study Procedure provided by the University of 
Glasgow. 
 
Patient safety issues 
Patients will be informed in the participant information sheet sent out prior to their 
appointment that they are not required to take part in this study and that not doing so will 
have no effect on their current or future treatment. Participants who express distress will be 
followed up in line with the current processes in place in the clinic. Their DT and HADS 
scores will be communicated to the Parkinson ’s disease team as part of their care pathway. If 
concerns are raised the clinical team will initiate their routine clinical care and direct referrals 
if required including accessing neuropsychology and clinical health psychology as part of 
standard practice. 
Ethical Issues 
An NHS Research Ethics Committee and the Research and Development Department in NHS 
A&A will be contacted for approval of the proposed research. 
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Financial Issues 
Item Unit Cost 
(£) 
Number required Total 
(£) 
Postage of 
Information Sheet 
and DT prior to 
appointment 
0.62 150* 93.00 
Postage of pre-paid 
envelopes 
0.62 55** participants (***estimating half the 
sample posting back their questionnaires) 
34.10 
Printing Costs 0.05 Information sheet (2 pages) x 150* 
+ 
DT x 150* (time point 1) 
+ 
Consent form (2 copies, one for primary 
researcher and one for participant) x 110**  
+ 
DT x 110** (time point 2) 
= 
780 
39.00 
Photocopy costs 0.05 HADS x 110 
+ 
Additional Information Questionnaire x 
110 
= 
220 
11.00 
À4 envelopes box of 
250 
9.01 1 box 9.01 
Total     186.11 
*At least 102 participants are required for the study. However, if we assume a 70% uptake 
rate, then approx. 150 people will need to be asked to take part in the study. 
**Assuming 110 people take part in the study 
*** Due to the increased likelihood if mobility issues, carer/family/support staff waiting for 
the individual after their clinic appointment and having other appointments/activities to 
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attend, and the increased likelihood that transportation by ambulance will be required for 
participants, the choice of completing questionnaires at a later date may be preferred by a 
large portion of participants. 
 
Proposed Timetable 
Application to ethics and R&D: February 2019 
Recruitment commencement: April/May 2019 
Data analysis: May 2020 
Writing-up: June-July 2020 
Practical Applications 
If the DT is found to be a valid measure to detect distress in people with IPD it may 
encourage clinicians to use DT to assess distress in this population in a busy clinical setting. 
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Participant ID____________ Date completed: ________________Pre/post: 
 
  
1)  PLEASE CIRCLE THE 
NUMBER (0-10) that best 
describes in general how much 
distress you have been 
experiencing over the past week, 
including today. 
  
 
2)   If any of the following has been a problem for you over the past 
week,  
including today, please tick the box next to it.  Leave it blank if it 
does not apply to you.   
  
     Physical Problems: 
 Your Appearance 
 Bathing or Dressing 
 Dribbling Saliva 
 Swallow problems 
 Eating/Appetite 
 Change in weight 
 Sore/Dry mouth 
 Eating or Appetite 
 Nausea/Vomiting 
 Urinary problems 
 Bowel problems 
 Sleep problems 
 Nightmares 
 Acting out in sleep 
 Need to move legs at 
night 
 Day time sleepiness 
 Fatigue or Tiredness 
 Swollen legs 
 Pain 
 Sweats 
 Sexual concerns 
 Taking medication 
 
    Motor issues: 
 Tremor 
 Fine motor control 
 Walking 
 Stiffness  
 Weakness 
 Freezing 
 Bed/Chair mobility 
 Falls 
  
    Cognitive Issues: 
 Memory  
 Speed of thinking 
 Concentration& attention  
 Judging distance/Space  
 Odd bizarre behaviour  
 Impulsive  
  
    Practical Problems: 
 Caring responsibilities 
 Finances, work  
 Housing       
 Transport/Driving  
  
Family Problems: 
 Relationship with children 
 Relationship with partner 
 Relationship with relatives 
/  
     friends 
 Burden (on family, friends 
etc) 
  
Emotional Problems: 
 Sadness or depression  
 Loneliness or isolation 
 Hopelessness 
 Worry, fear or anxiety 
 Loss of control or freedom 
 Anger or frustration 
 Seeing/Hearing things not 
there 
  
Spiritual Problems: 
 Spiritual concerns 
 Religious concerns  
 Anything else 
  
 
  
Any other problems not mentioned above? 
_______________________________________________________________________________
___ 
  
 3) If you ticked any boxes above, please choose three main problems you would like to 
discuss at your appointment today: 
 
1.______________________2.______________________3.______________________ 
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Appendix B 
 
RESEARCH EQUIPMENT, CONSUMABLES AND EXPENSES  
 
 
Trainee …………………2356262R ……………………………………………………………………       
 
Year of Course …………………2nd…year……….    Intake Year………2017………….. 
 
Please refer to latest stationary costs list (available from student support team) 
 
 
Item 
 
Details and Amount 
Required 
 
Cost or Specify if to 
Request to Borrow from 
Department 
 
Stationary 
 
 
A4 envelopes 100 (box of 
250 quoted on ‘Stationary 
costs 2015’ handout) 
 
 
 
Subtotal: £9.01 
 
Postage 
 
 
0.62 X 205  
 
 
Subtotal: £127.10 
 
Photocopying and Laser 
Printing   
Information sheet (2 
pages) x 150 
+ 
DT x 150 (time point 1) 
+ 
Consent form (2 copies, 
one for primary 
researcher and one for 
participant) x 110 
+ 
 
 
 
 
Subtotal: £50.00 
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DT x 110 (time point 2) 
= 
780 
 
HADS x 110 
+ 
Additional Information 
Questionnaire x 110 
= 
220 
 
Total =1,000 
 
Equipment and Software 
 
  
 
 
Subtotal: 
 
Measures 
 
 
  
 
 
Subtotal: 
 
Miscellaneous 
 
 
  
 
 
Subtotal: 
Total  £186.11 
 
For any request over £200 please provide further justification for all items that contribute to a high 
total cost estimate. Please also provide justification if costing for an honorarium: 
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Trainee Signature…………………………………… …   Date……………………… 
 
Supervisor’s Signature ………………………………..    Date ……………………… 
 
 
 
 
 
 
 
  
123 
 
Appendix C 
WEST OF SCOTLAND/ UNIVERSITY OF GLASGOW 
DOCTORATE IN CLINICAL PSYCHOLOGY 
 
HEALTH AND SAFETY FOR RESEARCHERS 
 
 
1. Title of Project Validation of the Distress Thermometer with 
People with Parkinson’s Disease  
 
2. Trainee 2356262R 
3. University Supervisor ##### 
4. Other Supervisor(s)  
5. Local Lead Clinician  
6. Participants:  (age,  group or sub-
group, pre- or post-treatment, etc) 
Idiopathic Parkinson’s Disease individuals  
7. Procedures to be applied  
(e.g., questionnaire, interview, etc) 
 
 
 
Three measures – Distress Thermometer (time 
point one – before clinic appointment and time 
point two – after clinic appointment); Hospital 
Anxiety and Depression Scale (HADS); Brief 
demographic questionnaire (asking about marital 
and employment status and whether distress 
levels have changed since DT time point one and 
if so, why. 
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8. Setting (where will procedures be 
carried out?) 
i) Details of all settings 
 
 
 
 
Movement Disorder Clinic – room booked in 
MDC. 
Home visits – if necessary i.e. participant cannot 
stay after their MDC appointment. 
 ii) Are home visits involved  Y 
 
WEST OF SCOTLAND / UNIVERSITY OF GLASGOW 
DOCTORATE IN CLINICAL PSYCHOLOGY 
 
HEALTH AND SAFETY FOR RESEARCHERS 
 
 
9. Potential Risk Factors Considered 
(for researcher and participant 
safety): 
i) Participants 
ii) Procedures 
iii) Settings 
       
 
 
 
Potential for violence and aggression from 
participants. Potential for participants to become 
fatigued during the course of the study. 
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10. . 10. Actions to minimise 
risk (refer to 9)  
i) Participants 
ii) Procedures 
iii) Settings 
 
 
 
 
 
 
Participants energy levels will be observed and 
monitored by the primary researcher 
For home visits: 
Both the Lone Working Policy for NHS Ayrshire 
and Arran and the Lone Study Procedure for 
students of University of Glasgow will be 
followed if home visits are necessary. Assess 
potential risk before going on home visit e.g. if 
there are any dogs on the premises.  
Participants who have been seen recently by a 
member of the clinical team involved with the 
patient and a risk assessment has been carried 
out. If the participant has had no recent 
involvement with a clinical team then a home 
visit will not be conducted. 
Discuss potential for risk with a member of the 
clinical team who has seen the patient recently.  
If there is doubt regarding level of risk, I will 
discuss with their University supervisor and/or a 
senior member of the clinical team that have 
responsibility for management of the patient. 
The overall appraisal of risk will take into 
account what is known about the participant, a 
risk assessment of their living environment by 
the clinical team and consideration of the 
geographical setting of the visit. This will include 
assessment of any risk associated with travelling 
to and from the participant’s home. Home visits 
will be undertaken only within normal work hours 
i.e. 9am -5pm. 
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Trainee signature:  ............................................................ Date:  ......................................  
 
University supervisor signature: ...................................................  Date: .............................. 
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